NCT01168921
Phase II Eltrombopag in Chronic Lymphocytic Leukemia (CLL) No drug interventions treatment 2 completed NCT06073821
Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL) No drug interventions treatment 3 recruiting NCT01675102
Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in 17p- Chronic Lymphocytic Leukemia (CLL) No drug interventions Not Available Not Available completed NCT05246345
Venetoclax Resistance Landscape in Chronic Lymphocytic Leukemia No drug interventions Not Available Not Available recruiting NCT00546793
Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL treatment 1 / 2 completed NCT00636909
Nonmyeloablative Allo SCT for the Treatment of Hematologic Disorders treatment 2 completed NCT03283137
Combination of Pembrolizumab With TGR-1202 in Patients With Relapsed/Refractory CLL and B-cell NHL treatment 1 active_not_recruiting NCT01199575
Phase II Trial of Revlimid® and Rituximab for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) treatment 2 completed NCT00021749
Phase I/II Study of Genasense in Patients With Chronic Lymphocytic Leukemia No drug interventions treatment 1 / 2 completed NCT04016636
A Study to Evaluate Impact of Ibrutinib on the Quality of Life (QOL) in Patients With Chronic Lymphocytic Leukemia No drug interventions Not Available Not Available completed NCT01465334
Ofatumumab With High Dose Methylprednisone Followed by Ofatumumab and Alemtuzumab in 17p CLL treatment 2 terminated NCT03639324
Rituximab, Idelalisib, and Venetoclax in Relapsed/Refractory CLL/SLL No drug interventions treatment 1 withdrawn NCT02362035
ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies treatment 1 / 2 active_not_recruiting NCT03524235
Haploidentical Stem Cell Transplant With Prophylactic Natural Killer DLI for Lymphoma, Multiple Myeloma, and CLL treatment 1 active_not_recruiting NCT04806035
Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia treatment 1 terminated NCT03868722
Acalabrutinib and Venetoclax Treatment of Newly Diagnosed Patients With CLL at High Risk of Infection or Early Treatment prevention 2 / 3 recruiting NCT05517265
Acalabrutinib in Patients With Chronic Lymphocytic Leukemia With Direct Oral Anticoagulation (CICERO) Not Available Not Available recruiting NCT05316831
Immune Response After Pneumococcal Vaccination in Patient With Chronic Lymphocytic Leukemia No drug interventions prevention 4 completed NCT04746092
The Capability of Haemato-oncology Patients to Generate Antibodies Against COVID-19 No drug interventions Not Available Not Available unknown_status NCT06557304
The Real World Study of BTK Inhibitor in the Treatment of Chronic Lymphocytic Leukemia in China No drug interventions Not Available Not Available not_yet_recruiting NCT02377869
Heavy Light Chain in Chronic Lymphocytic Leukemia No drug interventions Not Available Not Available unknown_status NCT03919214
Hypertension Management in Cancer Patients No drug interventions supportive_care Not Available terminated NCT00628238
Multi-center Trial of Revlimid® and Rituximab, for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL) No drug interventions treatment 2 unknown_status NCT01191190
Ofatumumab and High-dose Methylprednisolone in Patients With Chronic Lymphocytic Leukemia (CLL) No drug interventions treatment 2 completed NCT01703364
Fludarabine/Rituximab Combined With Escalating Doses of Lenalidomide in Untreated CLL No drug interventions treatment 1 / 2 completed NCT06489184
The Real World Study of Zanubrutinib in the Treatment of Chronic Lymphocytic Leukemia in China No drug interventions Not Available Not Available not_yet_recruiting NCT03231579
Chronic Lymphocytic Leukemia Electronic Patient Reported Outcomes Study No drug interventions Not Available Not Available completed NCT05869279
Allogeneic CARCIK-CD19 in Adults/Pediatric B-cell NHL or Chronic Lymphocytic Leukemia No drug interventions treatment 1 / 2 recruiting NCT05947851
A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010) No drug interventions treatment 3 recruiting NCT00792077
A Pilot Study to Investigate the Effect of Cytotoxic Therapy and/or Radiotherapy on Cancer Related Sleep Disturbances in CLL and Breast Cancer Patients Experiencing Fatigue No drug interventions treatment 2 completed NCT01862445
Retrospective Study: Efficacy and Safety of Chlorambucil + Rituximab in CLL Patients No drug interventions Not Available Not Available unknown_status NCT04512105
Pitavastatin in Combination With Venetoclax for Chronic Lymphocytic Leukemia or Acute Myeloid Leukemia No drug interventions treatment 1 active_not_recruiting NCT05610228
Study of the Metabolism in the Lymphatic Niche of CLL No drug interventions Not Available Not Available recruiting NCT02046928
Safety, Tolerability and Efficacy of A6 in Patients With Chronic Lymphocytic Leukemia (CLL) No drug interventions treatment 2 terminated NCT04640909
Impact of Treatment With Targeted Therapies on the Generation of CAR T Cells in CLL Patients No drug interventions basic_science Not Available recruiting NCT03572634
Phase 1/2 Study of TP-0903 (an Inhibitor of AXL Kinase) in Patients With Previously Treated CLL No drug interventions treatment 1 / 2 terminated NCT01397916
Indoleamine 2,3-dioxygenase (IDO) Activity in Patients With Chronic Lymphocytic Leukemia (CLL) No drug interventions Not Available Not Available completed NCT01532635
A Two-Step Approach to Bone Marrow Transplant Using Cells From Two Partially-Matched Relatives No drug interventions treatment 2 terminated NCT02229422
A Study of Obinutuzumab(GA101) in Combination With High-Dose Methylprednisolone(HDMP) in Chronic Lymphocytic Leukemia(CLL) Patients (GA101 & HDMP) No drug interventions treatment 1 / 2 active_not_recruiting NCT04923048
A Safety, Tolerability, Pharmacokinetics and Efficacy Study of GB261 in B-Cell NHL and CLL. No drug interventions treatment 1 / 2 recruiting NCT02828774
Peptide-drug-conjugates for Personalized, Targeted Therapy of Chronic Lymphocytic Leukemia No drug interventions Not Available Not Available unknown_status NCT00535873
Lenalidomide as Initial Treatment of Patients With Chronic Lymphocytic Leukemia (CLL) Age 65 and Older No drug interventions treatment 2 completed NCT04694560
A Time-Limited Approach to Treatment With Ibrutinib for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma No drug interventions Not Available Not Available withdrawn NCT04639362
CLL Induction Treatment With Venetoclax and Ibrutinib, Followed by Ibrutinib and Obinutuzumab in Patients With MRD. No drug interventions treatment 2 active_not_recruiting NCT00185692
Allogeneic Transplantation From Related Haploidentical Donors No drug interventions treatment 2 completed NCT02863692
Registry of the German CLL Study Group No drug interventions Not Available Not Available recruiting NCT03997968
A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors No drug interventions treatment 1 / 2 active_not_recruiting NCT03113695
Obinutuzumab, High Dose Methylprednisolone (HDMP), and Lenalidomide for the Treatment of Patients With Richter's Syndrome No drug interventions treatment 1 completed NCT00533923
Nonmyeloablative Allogeneic Stem Cell Transplantation From HLA-Matched Unrelated Donor for the Treatment of Hematologic Disorders No drug interventions treatment 2 completed NCT05209308
Rituximab Plus Venetoclax in Combination With Zandelisib in Subjects With CLL No drug interventions treatment 2 withdrawn NCT06506643
Safety and Efficacy of KLS-1 Monotherapy in Malignant Neoplasms No drug interventions treatment 1 / 2 active_not_recruiting NCT03294980
Chronic Lymphoid Leukaemia Observatory in Finistere Area, France No drug interventions Not Available Not Available recruiting NCT00919321
The Duration of Humoral Immunity and the Memory Cell Function After Vaccination With 7-valent Pneumococcal Conjugate Vaccine in CLL No drug interventions prevention 4 completed NCT00458679
Treatment of B-Chronic Lymphocytic Leukemia (B-CLL) With Autologous CD40 Ligand and IL-2-Expressing Tumor Cells No drug interventions treatment 1 completed NCT01125787
Clinical Protocol for the Treatment of Patients With Previously Untreated Chronic Lymphocytic Leukemia With a Combination of Bendamustine and Ofatumumab treatment 2 terminated NCT04488354
Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T No drug interventions other 1 enrolling_by_invitation NCT00840853
Multi-virus CTLs Expressing CD19 Chimeric Receptors, CD19 Positive Malignancies Post SCT, MULTIPRAT treatment 1 active_not_recruiting NCT05144347
Study of XL114 in Subjects With Non-Hodgkin's Lymphoma No drug interventions treatment 1 terminated NCT01768845
Unrelated Umbilical Cord Blood (UBC)Transplantation No drug interventions treatment Not Available completed NCT03588598
Safety, Tolerability, and Pharmacokinetics of SHC014748M in Patients With Indolent B-Cell Hematologic Malignancies No drug interventions treatment 1 unknown_status NCT01885897
IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT treatment 1 / 2 completed NCT03824483
Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL) treatment 2 recruiting NCT04655261
Study of Oral Venetoclax Tablets in Combination With Intravenous Obinutuzumab Injection to Assess Achievement of Best Response in Adult Participants With Chronic Lymphocytic Leukemia No drug interventions Not Available Not Available terminated NCT03580928
Acalabrutinib, Venetoclax, and Obinutuzumab for Initial Therapy of CLL treatment 2 active_not_recruiting NCT02136511
Expanded Access for Idelalisib in Combination With Rituximab in Chronic Lymphocytic Leukemia Not Available Not Available approved_for_marketing NCT00923507
Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL) No drug interventions Not Available Not Available recruiting NCT05908409
A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies No drug interventions treatment 1 / 2 recruiting NCT02966756
A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma treatment 2 recruiting NCT03406156
A Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination Therapy treatment 3 completed NCT03547115
A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AML treatment 1 recruiting NCT01463852
A Study of the Effect of Vinca Alkaloids on c-Jun N-terminal Kinase (JNK) Phosphorylation in Patients With Chronic Lymphocytic Leukemia (CLL) basic_science 0 terminated NCT01532700
An Open-Label Phase 2 Study of Ofatumumab (Arzerra) in Combination With Oral GSK2110183 in the Treatment of Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL) treatment 2 completed NCT01754870
Phase II Study of Bendamustine and Rituximab Induction Chemoimmunotherapy Followed by Maintenance Rituximab (Rituxan®) and Lenalidomide (Revlimid®) in Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL) treatment 2 withdrawn NCT01758042
Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood Disorders No drug interventions treatment Not Available recruiting NCT04419519
Assessing Minimal Residual Disease by Next- Generation Sequencing to Minimize Exposure in People With CLL or SLL Who Have Been Treated With Venetoclax treatment 2 recruiting NCT01517035
Improving Blood Stem Cell Collection and Transplant Procedures No drug interventions treatment 1 / 2 completed NCT01203930
A Study of Idelalisib and Rituximab in Elderly Patients With Untreated CLL or SLL treatment 2 terminated NCT03771157
Serologic Response to SHINGRIX Vaccine in Patients With CLL and WM Treated With BTK Inhibitors supportive_care 0 completed NCT04186520
CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies No drug interventions treatment 1 / 2 recruiting NCT01976520
Vaccine Therapy for Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) No drug interventions treatment 1 unknown_status NCT02980731
A Study Evaluating the Impact of Venetoclax on the Quality of Life for Subjects With Relapsed (Your Cancer Has Come Back) or Refractory (no Response to Previous Cancer Treatments) Chronic Lymphocytic Leukemia (CLL) While Receiving Venetoclax Monotherapy (a Single Agent). treatment 3 completed NCT00439231
Lenalidomide in Previously Treated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma treatment 2 completed NCT03085173
A Trial of "Armored" CAR T Cells Targeting CD19 For Patients With Relapsed CD19+ Hematologic Malignancies No drug interventions treatment 1 active_not_recruiting NCT01419691
Phase I and II Study of Auranofin in Chronic Lymphocytic Leukemia (CLL) treatment 2 completed NCT02086591
A Phase II Study of Doxycycline in Relapsed NHL treatment 2 terminated NCT03788291
Acalabrutinib and High Frequency Low Dose Subcutaneous Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma treatment 2 active_not_recruiting NCT02200380
A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell Mobilization in Matched Related Allogeneic Donor/Recipient Sibling Transplant Pairs treatment 2 terminated NCT02793544
HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide No drug interventions treatment 2 completed NCT04215367
Dietary Intervention With High Phenolic EVOO in CLL No drug interventions treatment Not Available completed NCT04447768
The Combination of Venetoclax and Obinutuzumab in People With Chronic Lymphocytic Leukemia (CLL) No drug interventions treatment 2 active_not_recruiting NCT03659669
A Study to Describe the Effectiveness and Safety of Venetoclax Treatment in Chronic Lymphocytic Leukemia (CLL) Patients in Routine Clinical Practice No drug interventions Not Available Not Available suspended NCT00640523
Phase II Study of Forodesine in Subjects With Chronic Lymphocytic Leukemia (CLL) No drug interventions treatment 2 completed NCT04767308
Safety and Efficacy of CT125A Cells for Treatment of Relapsed/Refractory CD5+ Hematopoietic Malignancies No drug interventions treatment 0 unknown_status NCT01527838
Single Treatment With FT1050 of an Ex-vivo Modulated Umbilical Cord Blood Unit No drug interventions treatment 1 completed NCT00694590
Study of AMD3100 (Plerixafor) and Rituximab in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No drug interventions treatment 1 completed NCT01050764
Haploidentical Allogeneic Transplant With Post-transplant Infusion of Regulatory T-cells No drug interventions treatment 1 / 2 terminated NCT05724121
Observational Study of Cardiac Arrhythmias During Treatment With BTK Inhibitors or Venetoclax No drug interventions Not Available Not Available recruiting NCT04209621
Duvelisib for Ibrutinib-Resistant Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma No drug interventions treatment 2 terminated NCT02582879
informCLL™: A Disease Registry for Patients With Chronic Lymphocytic Leukemia No drug interventions Not Available Not Available completed NCT01087333
Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer Treatment No drug interventions Not Available Not Available recruiting NCT01500733
PCI-32765 for Special Cases of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No drug interventions treatment 2 active_not_recruiting NCT01466153
A Phase 2, Multicenter, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) No drug interventions treatment 2 completed NCT02371577
Evaluation of the Immune Restoration Potential Of Lenalidomide No drug interventions treatment 2 withdrawn NCT00664677
Phase 1 Study of Terameprocol (EM-1421) in Patients With Leukemia No drug interventions treatment 1 terminated NCT01131247
PH2 Trial in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) With a Combination of Bendamustine & Ofatumumab No drug interventions treatment 2 withdrawn NCT00889798
Tumor Registry of Lymphatic Neoplasia No drug interventions Not Available Not Available completed NCT00467961
Stem Cell Transplantation for Patients With Cancers of the Blood No drug interventions treatment 2 completed NCT02226861
Ultra-Low Dose IL-2 Therapy as GVHD Prophylaxis in Haploidentical Allogeneic Stem Cell Transplantation No drug interventions prevention 1 completed NCT01580228
A Phase 3 Study Comparing Dinaciclib Versus Ofatumumab in Patients With Refractory Chronic Lymphocytic Leukemia (P07714) No drug interventions treatment 3 completed NCT00710528
Dose Escalation Study of CAL-101 in Select Relapsed or Refractory Hematologic Malignancies No drug interventions treatment 1 completed NCT06043011
Registry Platform Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic Neoplasms No drug interventions Not Available Not Available recruiting NCT01647971
Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma No drug interventions treatment 1 / 2 completed NCT01145209
Ofatumumab-based Induction Chemoimmunotherapy in Previously Untreated Patients With CLL/SLL No drug interventions treatment 2 completed NCT04198415
A Study of the Safety and Efficacy of Venetoclax in Japanese Participants With Relapsed and Refractory Chronic Lymphocytic Leukemia (Including Small Lymphocytic Leukemia) No drug interventions Not Available Not Available completed NCT04685915
Copanlisib Plus Ibrutinib or Acalabrutinib in R/R CLL No drug interventions treatment 2 withdrawn NCT04830137
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies No drug interventions treatment 1 recruiting NCT05720052
A Study of MS-553 in Patients With Relapsed or Refractory B-cell Lymphoma No drug interventions treatment 1 / 2 terminated NCT02580552
Safety, Tolerability and Pharmacokinetics of MRG-106 in Patients With Mycosis Fungoides (MF), CLL, DLBCL or ATLL No drug interventions treatment 1 completed NCT04758975
Venetoclax, Rituximab and Ibrutinib in TN Patients With CLL Undetectable Minimal Residual Disease (uMRD) in Treatment-naïve Patients With Chronic Lymphocytic Leukemia (CLL) No drug interventions treatment 2 recruiting NCT00614042
Phase 1/1b Study of TRU-016 in Patients With Previously Treated CLL or Select Subtypes of Non-Hodgkin's Lymphoma No drug interventions treatment 1 completed NCT01117142
A Study of the Kinetics of Lymphoid Cells in Patients With Monoclonal B-cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL), Mantle Cell Lymphoma (MCL) and Healthy Volunteers No drug interventions Not Available Not Available completed NCT04895436
Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL) No drug interventions treatment 2 recruiting NCT05105841
Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax in Combination With Intravenous (IV) Obinutuzumab or Oral Ibrutinib in Adult Participants With Untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) No drug interventions treatment 2 active_not_recruiting NCT04178317
A Study of the Safety and Efficacy of Venetoclax for Participants With Chronic Lymphocytic Leukemia (CLL) Used in Routine Clinical Practice No drug interventions Not Available Not Available recruiting NCT04072458
A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies No drug interventions treatment 1 recruiting NCT01241786
Study Examining the Combination of Revlimid (Lenalidomide)and Vidaza (Azacitidine) for Relapsed/Refractory CLL and SLL No drug interventions treatment 2 terminated NCT01723839
Phase II Protocol for CLL With Fludarabine and Cyclophosphamide With Rituximab (FCR) Plus Lenalidomide No drug interventions treatment 2 completed NCT05131022
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies No drug interventions treatment 1 recruiting NCT01520922
Ofatumumab Plus Bendamustine in Frontline and Relapsed Chronic Lymphocytic Leukaemia (CLL) No drug interventions treatment 2 completed NCT05168930
Zanubrutinib and Venetoclax in CLL (ZANU-VEN) No drug interventions treatment 2 recruiting NCT03873857
A Study to Assess Effectiveness of Venclexta (Venetoclax) in Patients With Relapse or Refractory Chronic Lymphocytic Leukemia in Routine Clinical Practice in Russian Federation No drug interventions Not Available Not Available completed NCT05708326
A Case Crossover Study of Intermittent Fasting in CLL/SLL No drug interventions prevention Not Available completed NCT00230282
Phase 2 Fludarabine, Cytoxan and FCCAM <Alemtuzumab> in Untreated B-Cell Chronic Lymphocytic Leukemia No drug interventions treatment 2 completed NCT03702231
Response to the SHINGRIX Varicella Zoster Virus (VZV) Vaccine in Chronic Lymphocytic Leukemia (CLL) and CLL Treated With Bruton's Tyrosine Kinase Inhibitor (BTK-I) No drug interventions basic_science 2 completed NCT02265731
Study Evaluating Venetoclax in Subjects With Hematological Malignancies No drug interventions treatment 1 / 2 completed NCT03400176
VAY736 in Combination With Ibrutinib in Patients With CLL on Ibrutinib No drug interventions treatment 1 terminated NCT03123029
Expanded Access to Venetoclax No drug interventions Not Available Not Available available NCT02269592
Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome No drug interventions Not Available Not Available recruiting NCT03342144
Study of the Use of Venetoclax in Participants With Chronic Lymphocytic Leukemia (CLL) Under Real-Life Setting No drug interventions Not Available Not Available active_not_recruiting NCT04285567
A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine And Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL (17P) or TP53 Mutation No drug interventions treatment 3 active_not_recruiting NCT06528301
A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies No drug interventions treatment 1 not_yet_recruiting NCT02553304
Molecular Features Underlying Racial Differences in Survival of Taiwanese Chronic Lymphocytic Leukemia Patients No drug interventions Not Available Not Available completed NCT01413568
Safety and Efficacy of POL6326 for Mobilization/Transplant of Sibling Donor in Patients With Hematologic Malignancies No drug interventions treatment 1 / 2 completed NCT04450069
CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies No drug interventions treatment 1 completed NCT01188681
Safety and Efficacy Study of TRU-016 Plus Bendamustine vs. Bendamustine in Relapsed Chronic Lymphocytic Leukemia No drug interventions treatment 1 / 2 completed NCT05557695
Observational Study of Acalabrutinib in Patients With Chronic Lymphocytic Leukaemia in the United Kingdom No drug interventions Not Available Not Available recruiting NCT02538614
Study of Idelalisib in Combination With BI 836826 in Participants With Chronic Lymphocytic Leukemia No drug interventions treatment 1 terminated NCT00185523
Allogeneic Transplantation for Patients With Acute Leukemia or Chronic Myelogenous Leukemia (CML) No drug interventions Not Available Not Available terminated NCT02914938
A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma No drug interventions treatment 1 terminated NCT00984165
Pilot Study of Radiation-Enhanced Allogeneic Cell Therapy for Progressive Hematologic Malignancy After Allogeneic Hematopoietic Stem Cell Transplantation No drug interventions treatment 2 terminated NCT00159003
Analysis of Genetic Factors Related to Predisposition and Prognosis of Hematological Malignancies in Israel No drug interventions Not Available Not Available completed NCT05260203
MargheRITA (Remote Intelligence for Therapeutic Adherence) No drug interventions supportive_care Not Available completed NCT02656303
A Study to Evaluate the Safety and Efficacy of Ublituximab in Combination With Umbralisib for Participants Previously Enrolled in Protocol UTX-TGR-304 No drug interventions treatment 2 terminated NCT00525603
CFAR Study in Patients With Chronic Lymphocytic Leukemia No drug interventions treatment 2 completed NCT03708003
Ibrutinib lead-in Followed by Venetoclax Plus Ibrutinib in Patients With RR CLL No drug interventions treatment 2 active_not_recruiting NCT01292603
A Study to Compare Subcutaneous Versus Intravenous MabThera (Rituximab) in Combination With Chemotherapy in Patients With Chronic Lymphocytic Leukemia No drug interventions treatment 1 completed NCT01243190
Ofatumumab for High-Risk Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) No drug interventions treatment 2 completed NCT03671590
Study of TG-1701, an Irreversible Bruton's Tyrosine Kinase Inhibitor, in Patients With B-Cell Malignancies No drug interventions treatment 1 terminated NCT02891590
Safety, Tolerability and PK of BTK Inhibitor DTRMWXHS-12 in Patients With B-Cell Lymphomas No drug interventions treatment 1 completed NCT05694364
Dose Escalation/Dose Expansion Study of PRGN-3007 UltraCAR-T Cells in Patients With Advanced Hematologic and Solid Tumor Malignancies No drug interventions treatment 1 recruiting NCT01109264
Bendamustine Hydrochloride Injection for Initial Treatment of Chronic Lymphocytic Leukemia No drug interventions treatment 2 completed NCT00600964
A Phase I/II Study of GX15-070MS in Untreated CLL No drug interventions treatment 1 completed NCT03980002
A Prospective Multicenter Phase 2 Study of FCR/BR Alternating With Ibrutinib in Treatment-naive Patients With CLL No drug interventions treatment 2 recruiting NCT04269902
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study No drug interventions treatment 3 recruiting NCT00771602
Alemtuzumab + Rituximab Consolidation in CLL No drug interventions treatment 2 terminated NCT03153202
Study to Evaluate the Safety and Preliminary Efficacy of Ibrutinib and Pembrolizumab in Patients With Chronic Lymphocytic Leukemia (CLL) or Mantle Cell Lymphoma (MCL) No drug interventions treatment 1 / 2 recruiting NCT04935684
Faecal Microbiota Transplantation After Allogeneic Stem Cell Transplantation No drug interventions treatment 2 recruiting NCT05878184
Study Evaluating SC291 in Subjects With r/r B-cell Malignancies (ARDENT) No drug interventions treatment 1 recruiting NCT02080884
An Observational Study Examining the Effect of Added MabThera Therapy in Patients With Untreated Chronic Lymphocytic Leukemia No drug interventions Not Available Not Available completed NCT00898079
Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer No drug interventions Not Available Not Available completed NCT05555979
A Study to Assess Change in Patient Experience in Adult Participants With Chronic Lymphocytic Leukemia (CLL) Receiving Oral Venetoclax Tablets + Intravenous Rituximab or Bruton's Tyrosine Kinase Inhibitors Tablets in the United Kingdom No drug interventions Not Available Not Available completed NCT04159779
A Study of Clinical Outcomes in Chronic Lymphocytic Leukemia (CLL) Patients Treated With Venetoclax in Greece No drug interventions Not Available Not Available active_not_recruiting NCT01005979
A Phase I Trial Using Cyclophosphamide, Rituximab and Revlimid (CR2) for the Treatment of Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL) and Small Lymphocytic Lymphoma (SLL) No drug interventions treatment 1 terminated NCT05254743
A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) No drug interventions treatment 3 active_not_recruiting NCT01905943
A Safety and Efficacy Study of Obinutuzumab Alone or in Combination With Chemotherapy in Participants With Chronic Lymphocytic Leukemia No drug interventions treatment 3 completed NCT02194387
Energy Balance Interventions in Increasing Physical Activity in Breast Cancer Gene Positive Patients, Lynch Syndrome-Positive Patients, CLL Survivors or High-Risk Family Members No drug interventions prevention Not Available active_not_recruiting NCT01722487
Open-label Phase 3 BTK Inhibitor Ibrutinib vs Chlorambucil Patients 65 Years or Older With Treatment-naive CLL or SLL treatment 3 completed NCT00990587
Study Evaluating the Tolerance and Biologic Activity of Oral Ciclopirox Olamine in Patients With Relapsed or Refractory Hematologic Malignancy treatment 1 completed NCT00081887
Study of Weekly Clofarabine for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia treatment 1 terminated NCT02135133
A Study of Idelalisib (GS1101, CAL101) + Ofatumumab in Previously Untreated CLL/SLL treatment 2 active_not_recruiting NCT03336333
A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL treatment 3 active_not_recruiting NCT05212233
Financial Difficulty in Patients With Blood Cancer No drug interventions Not Available Not Available recruiting NCT05844033
Biomarker for Infection Risk in CLL and MM No drug interventions Not Available Not Available recruiting NCT00709033
T-cells or EBV Specific CTLs, Advanced B-Cell NHL and CLL No drug interventions treatment 1 active_not_recruiting NCT00464633
Alvocidib in Patients With Previously Treated Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia Arising From Chronic Lymphocytic Leukemia (CLL) treatment 2 completed NCT04545333
The clonoSEQ® Watch Registry No drug interventions Not Available Not Available terminated NCT06364033
Biological and Clinical Efficacy of Shingrix in Patients With CLL No drug interventions basic_science Not Available not_yet_recruiting NCT04624633
Acalabrutinib, Umbralisib, and Ublituximab (AU2) In Relapsed and Untreated CLL treatment 2 active_not_recruiting NCT00275054
Rituximab, Fludarabine, and Cyclophosphamide or Observation Alone in Treating Patients With Stage 0, Stage I, or Stage II Chronic Lymphocytic Leukemia treatment 3 completed NCT01627054
A Phase II Study of AT7519M, a CDK Inhibitor, in Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia No drug interventions treatment 2 completed NCT03379051
Phase I/II Study of Venetoclax or Lenalidomide in Combination With Ublituximab and Umbralisib in Subjects With Relapsed or Refractory CLL/SLL and NHL treatment 1 / 2 terminated NCT02427451
Bcl-2 Inhibitor GDC-0199 in Combination With Obinutuzumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or Previously Untreated Chronic Lymphocytic Leukemia treatment 1 / 2 active_not_recruiting NCT04595851
Pharmacists Coordinated Care Oncology Model (PCOM) for Patients Taking Oral Anti-cancer Medications No drug interventions health_services_research Not Available terminated NCT00090051
FCR Versus FC Alone in the Treatment of Chronic Lymphocytic Leukemia (CLL) in Relapsed Patients treatment 3 completed NCT03059251
Observational Study: Safety and Effectiveness of Obinutuzumab in Chronic Lymphocytic Leukemia in Argentina Not Available Not Available completed NCT01087151
A Study of ABT-263 in Combination With Dose-Intensive Rituximab, or Dose-Intensive Rituximab Alone, in Previously Untreated Patients With B-Cell, Chronic Lymphocytic Leukemia (CLL) treatment 2 completed NCT02290951
Study to Investigate the Safety and Tolerability of Odronextamab in Patients With CD20+ B-Cell Malignancies treatment 1 active_not_recruiting NCT02231853
Phase I/II Trial of Early Infusion of Rapidly-generated Multivirus Specific T Cells (MVST) to Prevent Post Transplant Viral Infections No drug interventions prevention 1 terminated NCT05702853
Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL treatment 1 / 2 recruiting NCT01557777
Open-label Extension Study of Navitoclax in Subjects With Chronic Lymphocytic Leukemia (CLL) basic_science 2 completed NCT05999877
PICAROS - Acalabrutinib RWE on 1L CLL in Spain No drug interventions Not Available Not Available active_not_recruiting NCT03765177
CLIC-1901 for the Treatment of Patients With Relapsed/Refractory CD19 Positive Hematologic Malignancies No drug interventions treatment 1 / 2 recruiting NCT00807677
A Phase 1 Dose Escalation Study of TAK-901 in Subjects With Advanced Hematologic Malignancies treatment 1 completed NCT02553447
Cholecalciferol in Newly Diagnosed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia With Vitamin D Deficiency No drug interventions treatment Not Available active_not_recruiting NCT00829647
A Study Using Two Oral Chemotherapy Agents for Chronic Lymphocytic Leukemia treatment 1 / 2 withdrawn NCT04732845
Human AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Lymphoid Malignancies treatment 1 recruiting NCT03037645
Safety, PK, PD, and Antitumor Activity of Vecabrutinib (SNS-062) in B Lymphoid Cancers treatment 1 / 2 terminated NCT04790045
Lymph Node Microenvironment Modifications in Patients With CLL Treated With Venetoclax-based Regimens treatment 4 not_yet_recruiting NCT00916045
Pilot Study of Unrelated Cord Blood Transplantation treatment 2 terminated NCT04043845
ERK 1/2 Signaling in Ibrutinib Resistant B-cell Malignancies treatment 1 withdrawn NCT02981745
Study of Safety,Efficacy and Pharmacokinetics of CT-1530 in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia No drug interventions treatment 1 / 2 unknown_status NCT03884998
Copanlisib and Nivolumab in Treating Patients With Richter's Transformation or Transformed Indolent Non-Hodgkin Lymphoma treatment 1 active_not_recruiting NCT06520098
A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) treatment 2 not_yet_recruiting NCT02491398
Efficacy and Safety of Bendamustine Plus Rituximab in Chronic Lympocytic Leukemia Not Available Not Available completed NCT03615105
Donor Stem Cell Transplantation Using α/β+ T-lymphocyte Depleted Grafts From HLA Mismatched Donors treatment 2 terminated NCT01414205
A Study Comparing Obinutuzumab (RO5072759; GA101) 1000 Milligram (mg) Versus 2000 mg in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL) (GAGE) treatment 2 completed NCT05031897
Reduced-Intensity Conditioning for the Prevention of Treatment-Related Mortality in Patients Who Undergo a Hematopoietic Stem Cell Transplant treatment 2 recruiting NCT01486797
NOX-A12 in Combination With Bendamustine and Rituximab in Relapsed Chronic Lymphocytic Leukemia (CLL) treatment 2 completed NCT05950997
A Single Arm Study of Acalabrutinib Conbimed With Obinutuzumab in Chinese Patients With Previously Untreated CLL treatment Not Available recruiting NCT00779883
A Phase I Trial of Autologous CLL B Cells Transduced to Express Chimeric CD154 (ISF35) treatment 1 completed NCT01500083
Bendamustine Hydrochloride (HCl) in Indolent Non-Hodgkin's Lymphoma That Has Progressed During or Following Treatment With a Rituximab Regimen or Previously Untreated Chronic Lymphocytic Leukemia treatment 3 completed NCT00038883
Campath-1H and Allogeneic Blood Stem Cell Transplantation for Lymphoid Malignancies treatment Not Available terminated NCT04167683
Muscle Dysfunction in Patients With Hematological Diseases Referred to Stem Cell Transplant No drug interventions Not Available Not Available recruiting NCT01271283
Lenalidomide in Treating Patients With High-Risk Chronic Lymphocytic Leukemia treatment 2 withdrawn NCT02514083
A Phase II Study Using Ibrutinib and Short-Course Fludarabine in Treatment-Naive CLL treatment 2 active_not_recruiting NCT01500161
Pooled Unrelated Donor Umbilical Cord Blood Transplant For Hematologic Malignancy Needing Allogeneic Stem Cell Transplant Without Related HLA-Match treatment 2 terminated NCT00102661
Continuous Infusion of Campath-1H Followed by Subcutaneous Injections in Previously Treated Patients With Chronic Lymphocytic Leukemia treatment 2 completed NCT00608361
Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery treatment 1 completed NCT01013961
Rituximab and Alemtuzumab in Treating Older Patients With Progressive Chronic Lymphocytic Leukemia treatment 2 terminated NCT00096161
Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Cell Transplant treatment 2 completed NCT04908228
Fixed-duration Therapy With Ibrutinib and Obinutuzumab (GA-101) in Treatment-naïve Patients With CLL treatment 2 recruiting NCT00743028
Assess the Oral Bioavailability of New ABT-263 Formulations treatment 1 completed NCT04844528
Effects of Nicotinamide in Patients With Chronic Lymphocytic Leukemia (CLL) With History of Non-melanoma Skin Cancers (NMSC) treatment 2 recruiting NCT00100711
Study of Motexafin Gadolinium (MGd) in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma treatment 2 terminated NCT01161511
Safety and Tolerability of XmAb®5574 in Chronic Lymphocytic Leukemia treatment 1 completed NCT01300611
TXA127 in Enhancement of Engraftment in Adult Double Cord Blood Transplantation supportive_care 1 terminated NCT01459211
Pilot Study to Establish Safety & Efficacy of a Combination of Dexamethasone and Lenalidomide in Patients With Relapsed or Refractory Chronic Lymphocytic Leukaemia (CLL) treatment 2 completed NCT03609593
Bendamustine/Rituximab Followed by Venetoclax and Rituximab for Treatment of Chronic Lymphocytic Leukemia treatment 2 active_not_recruiting NCT00758693
Frontline Treatment With Bendamustine in Combination With Rituximab in Adults Age 65 or Older With Chronic Lymphocytic Leukemia (CLL) treatment 2 withdrawn NCT01868893
An Expanded Access, Open-Label Study of Obinutuzumab (GA101) Plus Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia treatment 2 completed NCT04965493
A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) treatment 3 recruiting NCT01181271
Tandem Auto-Allo Transplant for Lymphoma treatment 2 completed NCT00676871
A Study to Evaluate the Safety, Tolerability, and Antitumor Activity of Continuous Intravenous Infusion of MEDI-538 in Adults With B-Cell Chronic Lymphocytic Leukemia (CLL) treatment 1 / 2 withdrawn NCT02005471
A Study to Evaluate the Benefit of Venetoclax Plus Rituximab Compared With Bendamustine Plus Rituximab in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) treatment 3 completed NCT06170671
REAl-world Outcomes in CHronic Lymphocytic Leukemia Patients Receiving Acalabrutinib in Romania No drug interventions Not Available Not Available recruiting NCT03436771
Long-term Follow-up Study for Patients Previously Treated With a Juno CAR T-Cell Product No drug interventions Not Available Not Available terminated NCT05020678
NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers No drug interventions treatment 1 recruiting NCT02222688
UC-961 (Cirmtuzumab) in Relapsed or Refractory Chronic Lymphocytic Leukemia treatment 1 completed NCT02767388
Electrophysiological Biomarkers of Chemotherapy-related Cognitive Impairment and Recovery No drug interventions Not Available Not Available completed NCT01098188
LFB-R603 Dose Finding in Patients With Advanced Stage B-Chronic Lymphocytic Leukemia treatment 1 completed NCT01585688
Phase I/II Study of hLL1-DOX in Relapsed NHL and CLL No drug interventions treatment 1 / 2 terminated NCT03622788
Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell Transplant treatment 1 / 2 recruiting NCT00783588
A Phase I Extension Trial of Repeated Infusions of ISF35 treatment 1 completed NCT00719888
Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease treatment 2 active_not_recruiting NCT02500407
A Safety, Efficacy and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) treatment 1 / 2 active_not_recruiting NCT00290407
Rituximab Plus Beta-Glucan in Chronic Lymphocytic Leukemia(CLL)/Small Lymphocytic Lymphoma (SLL) treatment 2 terminated NCT04771507
A Pilot Study on Intermittent Ibrutinib in Patients With Advanced-phase Chronic Lymphocytic Leukemia (CLL) treatment 1 / 2 recruiting NCT00276809
Combination Chemotherapy, Total-Body Irradiation, and Alemtuzumab in Treating Patients Undergoing an Autologous Stem Cell Transplant for Stage I, Stage II, Stage III, or Stage IV Chronic Lymphocytic Leukemia treatment 2 completed NCT01567709
Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma treatment 1 completed NCT06224309
Preliminary Assessment of [18F]BL40 in PET/CT Scans No drug interventions Not Available Not Available not_yet_recruiting NCT00942409
Study of Repeat Intranodal Injections of Ad-ISF35 treatment 2 terminated NCT03316209
Identification of Occupational Exposures in Acute Hematologic Malignancy No drug interventions Not Available Not Available completed NCT01076556
Cyclophosphamide, Alvocidib, and Rituximab in Treating Patients With High Risk B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma treatment 1 terminated NCT01123356
Treatment of Chronic Lymphocytic Leukemia in Patients Previously Exposed to Rituximab treatment 2 completed NCT03207256
Extension Trial of Ublituximab and TGR-1202 in Combination or as Single Agents in Subjects Currently Receiving Treatment on Ublituximab and/or TGR-1202 Trials treatment 2 terminated NCT01510756
Sorafenib for the Treatment of Chronic Lymphocytic Leukemia (CLL) treatment 2 terminated NCT01400685
Lenalidomide Plus Bendamustine and Rituximab for Untreated CLL/SLL treatment 1 completed NCT04688385
Personalized Multi-peptide Vaccination in CLL Patients No drug interventions treatment 1 active_not_recruiting NCT02057185
Occupational Status and Hematological Disease No drug interventions Not Available Not Available completed NCT02440685
A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors treatment 1 / 2 terminated NCT01149915
Study of Hypoxia-Activated Prodrug TH-302 to Treat Advanced Leukemias treatment 1 completed NCT01081015
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry No drug interventions Not Available Not Available completed NCT02049515
A Phase 3 Extension Study of Duvelisib and Ofatumumab in Participants With CLL/SLL Previously Enrolled in Study IPI-145-07 treatment 3 completed NCT00962715
Reactogenicity, Immunogenicity of Trivalent Influenza Vaccine With Recombinant Interferon Alpha Among Chronic Lymphocytic Leukemia treatment 1 / 2 withdrawn NCT04665115
Ibrutinib for the Treatment of Patients With B-Cell Malignancies Who Are Infected With Coronavirus Disease 2019 (COVID-19) treatment 2 withdrawn NCT01484015
Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia treatment 1 completed NCT04867915
Study on the Diagnosis and Management of CLL in Italy by GIMEMA No drug interventions Not Available Not Available recruiting NCT03374137
Observational Study to Monitor Safety and Effectiveness of Obinutuzumab in Follicular Lymphoma or Previously Untreated Chronic Lymphocytic Leukemia Not Available Not Available completed NCT03076437
Anti-CD19 Chimeric Antigen Receptor (CAR)-Transduced T Cell Therapy for Patients With B Cell Malignancies No drug interventions treatment 1 / 2 completed NCT00496132
A Trial of the Safety of Escalating Doses of PRO131921 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia No drug interventions treatment 1 / 2 terminated NCT01113632
Ofatumumab for Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma treatment 2 completed NCT01699152
Phase 1 Study of TG02 Citrate in Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma treatment 1 completed NCT06536452
Hematopoiesis in MBL and CLL Versus Healthy Age-Matched Control Subjects No drug interventions Not Available Not Available recruiting NCT02294552
Post-transplantation Cyclophosphamide as GVHD Prophylaxis After HSCT treatment 2 completed NCT03560752
CMV-MVA Triplex Vaccination of Stem Cell Donors in Preventing CMV Viremia in Participants With Allogeneic Transplant supportive_care 1 active_not_recruiting NCT04189952
Acalabrutinib in Combination With R-ICE For Relapsed or Refractory Lymphoma treatment 2 terminated NCT06548152
AQUALIS:QoL of CLL Patients Treated With Acalabrutinib in France, Retrospective Study Based on Data From PLATON Database No drug interventions Not Available Not Available not_yet_recruiting NCT04887259
Trial of LAVA-051 in Patients With Relapsed/Refractory CLL, MM, or AML treatment 1 / 2 active_not_recruiting NCT03197259
Chronic Lymphocytic Leukemia Registry Study - Multicenter Prospective National Study No drug interventions Not Available Not Available recruiting NCT00632359
Lenalidomide in Chronic Lymphocytic Leukemia (CLL) Patients With Residual Disease treatment 2 completed NCT04716075
Acalabrutinib in CLL and MCL Patients Subjected to Allogeneic Hematopoietic Stem Cell Transplantation (alloSCT) treatment 2 active_not_recruiting NCT04796675
Cord Blood Derived Anti-CD19 CAR-Engineered NK Cells for B Lymphoid Malignancies treatment 1 unknown_status NCT00975975
Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer treatment 2 completed NCT00513175
Non-Myeloablative Allogeneic Stem Cell Transplantation With Matched Unrelated Donors for Treatment of Hematologic Malignancies, Renal Cell Carcinoma, and Aplastic Anemia No drug interventions Not Available Not Available completed NCT00562770
Oral Valganciclovir Versus Valacyclovir treatment 2 completed NCT00446342
Study of Intravenously Administered SNS-032 in Patients With Advanced B-lymphoid Malignancies treatment 1 completed NCT03943342
Ibrutinib and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia After Ibrutinib Resistance treatment 2 withdrawn NCT00309842
Myeloablative Umbilical Cord Blood Transplantation in Hematological Diseases treatment 2 completed NCT02242942
Comparison of the Treatments of Obinutuzumab + Venetoclax Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia treatment 3 active_not_recruiting NCT00864942
Trial of Bendamustine, Lenalidomide and Rituximab in Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma (NHL) treatment 1 completed NCT02381899
Observational Study in CLL Patients Receiving BR Not Available Not Available completed NCT01610999
Pilot Study of Lymphoid Tumor Microenvironmental Dysruption Prior to Autologous Stem Cell Transplantation treatment 1 terminated NCT03246906
Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation treatment 2 active_not_recruiting NCT04862806
Safety, Efficacy of BNT162b2 mRNA Vaccine in CLL No drug interventions diagnostic Not Available unknown_status NCT05388006
Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation From Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma treatment 2 recruiting NCT00233506
A Dose Finding Study of CpG in Patients With Chronic Lymphocytic Leukemia Who Have Been Previously Treated treatment 1 completed NCT04008706
Acalabrutinib Safety Study in Untreated and Relapsed or Refractory Chronic Lymphocytic Leukemia Patients treatment 3 active_not_recruiting NCT01369849
Akt Inhibitor MK2206, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma treatment 1 / 2 completed NCT01397149
Eltrombopag in Thrombocytopenic Chronic Lymphocytic Leukemia (CLL) Patients (CLL2S Study of GCLLSG) treatment 1 / 2 terminated NCT03150849
C-X-C Chemokine Receptor 4 in Chronic Lymphocytic Leukemia No drug interventions Not Available Not Available unknown_status NCT03162536
A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001) treatment 1 / 2 active_not_recruiting NCT05317936
Pirtobrutinib (LOXO-305) Consolidation for MRD Eradication in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL) Treated With Venetoclax treatment 2 recruiting NCT02048813
Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma treatment 3 active_not_recruiting NCT00868413
Study of ABT-263 When Administered in Combination With Either Fludarabine/Cyclophosphamide/Rituximab or Bendamustine/Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia treatment 1 completed NCT00193518
Arsenic Trioxide in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma treatment 2 completed NCT02296918
Acalabrutinib in Combination With Anti-CD20 and Venetoclax in Relapsed/Refractory or Untreated CLL/SLL/PLL treatment 1 active_not_recruiting NCT00028418
Clofarabine in Chronic Lymphocytic Leukemia treatment 1 completed NCT00038818
CD8 DLI for Patients With Relapse or Residual Disease Following Allogeneic Stem Cell Transplantation No drug interventions treatment Not Available terminated NCT01892618
Pneumococcal Vaccine in Untreated CLL Patients treatment 3 completed NCT04282018
Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab treatment 1 / 2 active_not_recruiting NCT02970318
A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL treatment 3 active_not_recruiting NCT00448019
FCR and Bevacizumab in the Treatment of Relapsed Chronic Lymphocytic Leukemia (CLL) treatment 2 completed NCT05677919
Pirtobrutinib and Venetoclax With MRD Detection for Previously Untreated Chronic Lymphocytic Leukemia treatment 2 recruiting NCT03601819
Pacritinib in Relapsed/Refractory Lymphoproliferative Disorders treatment 1 terminated NCT00337519
Allogeneic Stem Cell Transplantation in Chronic Lymphocytic Leukemia treatment 2 unknown_status NCT01013441
CD3/CD28 Bead Activated T-Cells Following Chemo-Immunotherapy in Patients With Chronic Lymphocytic Leukemia No drug interventions treatment 1 completed NCT04938141
MEOI and HRQoL in CLL Patients Treated With BTKis No drug interventions Not Available Not Available active_not_recruiting NCT01272817
Nonmyeloablative Allogeneic Transplant No drug interventions treatment Not Available completed NCT02669017
Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL) treatment 1 completed NCT02983617
Safety and Efficacy of the Combination of Tirabrutinib and Entospletinib With and Without Obinutuzumab in Adults With Chronic Lymphocytic Leukemia (CLL) treatment 2 completed NCT03516617
Acalabrutinib With or Without Obinutuzumab in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma treatment 2 recruiting NCT03514017
Ibrutinib and PD-1 Blockade in High Risk Lymphocytic Leukemia treatment 2 terminated NCT01634217
Inducible Regulatory T Cells (iTregs) in Non-Myeloablative Sibling Donor Peripheral Blood Stem Cell Transplantation No drug interventions treatment 1 completed NCT01460134
A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers treatment 1 completed NCT02784834
Dimethylfumarate (DMF) in Relapsed/Refractory CLL/SLL treatment 1 terminated NCT03939234
Peptide Vaccination With PD-L1 and PD-L2 Peptides in Untreated Chronic Lymphatic Leukemia. No drug interventions treatment 2 completed NCT03986034
Early Clonal Dynamics During Venetoclax Treatment for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) basic_science 2 recruiting NCT02396134
Vaccine Therapy in Reducing the Frequency of Cytomegalovirus Events in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant No drug interventions supportive_care 2 active_not_recruiting NCT00378534
Methods to Enhance the Safety and Effectiveness of Stem Cell Transplants treatment 2 completed NCT04657224
A Study of JNJ-64264681 and JNJ-67856633 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia No drug interventions treatment 1 active_not_recruiting NCT05091424
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia treatment 1 recruiting NCT00598624
Clinical Trial to Evaluate the Safety and Efficacy of Treosulfan Based Conditioning Prior to Allogeneic Haematopoietic Stem Cell Transplantation (HSCT) treatment 2 unknown_status NCT02157324
Acalabrutinib in Combination With ACP-319, for Treatment of Chronic Lymphocytic Leukemia treatment 1 active_not_recruiting NCT00060424
Fludarabine Phosphate and Total-Body Irradiation Before Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia treatment 2 completed NCT05006716
A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies No drug interventions treatment 1 / 2 recruiting NCT01682616
A Phase 1b Study Evaluating the Safety and Tolerability of ABT-199 in Combination With Rituximab in Subjects With Relapsed Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma treatment 1 completed NCT03734016
A Study of Zanubrutinib (BGB-3111) Versus Ibrutinib in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia treatment 3 completed NCT01497496
Ofatumumab/Methylprednisolone and Ofatumumab/Lenalidomide for Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) treatment 2 completed NCT06521996
M-CHOP in Richter´s Syndrome treatment 2 recruiting NCT01351896
Lenalidomide and Vaccine Therapy in Treating Patients With Early-Stage Asymptomatic Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma treatment 2 active_not_recruiting NCT05360758
Ibrutinib Adapted to Response in Patients With CLL No drug interventions Not Available Not Available not_yet_recruiting NCT00104858
Fludarabine Phosphate, Radiation Therapy, and Rituximab in Treating Patients Who Are Undergoing Donor Stem Cell Transplant Followed by Rituximab for High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma treatment 2 completed NCT00241358
Study Evaluating AMD3100 for Transplantation of Sibling Donor Stem Cells in Patients With Hematological Malignancies treatment 1 / 2 completed NCT04358458
First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas treatment 1 / 2 terminated NCT02890758
Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803 treatment 1 completed NCT03415035
Study Venetoclax Effectiveness and Real-Life Treatment Management in Participants With Chronic Lymphocytic Leukemia No drug interventions Not Available Not Available active_not_recruiting NCT01351935
Escalating Dose Study in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia treatment 1 completed NCT02661035
Allo HSCT Using RIC for Hematological Diseases treatment 2 completed NCT02345863
Sequential Regimen of Bendamustin [B] Followed by GA101 and Ibrutinib [I] in CLL Patients treatment 2 completed NCT02968563
Study to Evaluate the Safety and Efficacy of the Combination of Tirabrutinib and Idelalisib With and Without Obinutuzumab in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) treatment 2 completed NCT01408563
Reduced Intensity Double Umbilical Cord Blood Transplantation treatment 2 completed NCT01364363
Unrelated Donor Stem Cell Transplantation No drug interventions treatment Not Available completed NCT01066663
Pyrimethamine for the Treatment of Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma treatment 1 / 2 completed NCT01110863
Characterization of Proliferating Compartment in B-Cell Patients and in Healthy Aging Subjects No drug interventions Not Available Not Available completed NCT05602363
AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma No drug interventions treatment 1 recruiting NCT01178086
A Study on Rituximab (MabThera) in Participants With Chronic Lymphocytic Leukemia (CLL) Not Available Not Available completed NCT00001586
Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): DNA Microarray Gene Expression Analysis treatment 2 completed NCT02535286
Study of Immunotherapy in Combination With Ublituximab and Umbralisib in Patients With Relapsed-refractory CLL or Richter's Transformation treatment 1 completed NCT01890486
The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen No drug interventions Not Available Not Available recruiting NCT05718986
Familial B-cell Lymphoproliferative Disorders No drug interventions Not Available Not Available not_yet_recruiting NCT01804686
A Long-term Extension Study of PCI-32765 (Ibrutinib) treatment 3 enrolling_by_invitation NCT03333486
Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer treatment 2 active_not_recruiting NCT00934986
Natural Killer Cells Function in Patients With Chronic Lymphocytic Leukemia No drug interventions basic_science Not Available completed NCT01082939
Cyclophosphamide, Fludarabine, Alemtuzumab, and Rituximab (CFAR) for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) treatment 2 completed NCT01849939
Eradication of Residual Disease by Preemptive Immunointervention After Allogeneic Hematopoietic Stem Cells Transplantation in Chronic Lymphocytic Leukemia No drug interventions treatment 2 unknown_status NCT04501939
Cirmtuzumab Consolidation for Treatment of Patients With Detectable CLL on Venetoclax treatment 2 active_not_recruiting NCT03056339
Umbilical & Cord Blood (CB) Derived CAR-Engineered NK Cells for B Lymphoid Malignancies treatment 1 / 2 completed NCT04852822
Immune Response to SARS-CoV-2 (COVID-19) Vaccines in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No drug interventions Not Available Not Available terminated NCT05400122
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer treatment 1 recruiting NCT04560322
Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL treatment 2 recruiting NCT01832922
BR in Patients With CLL With Comorbidities and/or Renal Dysfunction treatment 1 completed NCT01353625
Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, and Hematologic Malignancies. treatment 1 completed NCT06151730
Evaluation of Hypertension Management and Cardiovascular Adverse Event Prevention in Patients With B-cell Malignancies Undergoing Treatment With Bruton Tyrosine Kinase Inhibitors, the HALT Study No drug interventions Not Available Not Available recruiting NCT00176930
Stem Cell Transplant for Hematological Malignancy treatment Not Available terminated NCT04502030
Double-blind, Randomized, Placebo-controlled, Prospective Phase III Study Evaluating Efficacy and Safety of Panzyga in Primary Infection Prophylaxis in Patients With Chronic Lymphocytic Leukemia ("PRO-SID" Study) prevention 3 recruiting NCT05153330
Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL No drug interventions treatment 1 recruiting NCT00319930
Phase 1, Dose-Escalation, Pharmacodynamic Study of IV CNF1010 in ZAP-70 Positive CLL treatment 1 terminated NCT01465230
Maintenance Therapy: Lenalidomide Following Bendamustine and Rituximab Induction Therapy for Chronic Lymphocytic Leukemia treatment 2 terminated NCT00735930
Lenalidomide and Alvocidib in Treating Patients With Relapsed or Refractory B-cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma treatment 1 completed NCT03844048
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial treatment 3 active_not_recruiting NCT04018248
BR101801 in Adult Patients With Advanced Hematologic Malignancies( Phase I) treatment 1 active_not_recruiting NCT01120457
First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody in Subjects With Acute Myelogenous Leukemia and Selected B-cell Cancers treatment 1 completed NCT00860457
Lenalidomide Following Fludarabine/Rituximab (FR) in Untreated Chronic Lymphocytic Leukemia (CLL) treatment 2 completed NCT04370457
MyPal ePRO-based Early Palliative Care System in Adult Patients With Hematologic Malignancies No drug interventions supportive_care Not Available unknown_status NCT00036257
Dose-Escalating and Safety Study of CP-461 in Patients With Chronic Lymphocytic Leukemia No drug interventions treatment 1 completed NCT02156726
Observational Study of Low Dose FCR in Elderly/Comorbid CLL/SLL: The Q-lite Project Not Available Not Available unknown_status NCT01300026
AMG 319 Lymphoid Malignancy FIH No drug interventions treatment 1 completed NCT01328626
A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma treatment 1 completed NCT00391066
Lumiliximab With Fludarabine, Cyclophosphamide, and Rituximab (FCR) Versus FCR Alone in Subjects With Relapsed Chronic Lymphocytic Leukemia (CLL) treatment 2 terminated NCT01767766
Evaluate the Safety and Efficacy of TGR 1202 in Patients With Relapsed or Refractory Hematologic Malignancies treatment 1 completed NCT05417165
Anti-pneumococcal Vaccine Strategy in Patients With Chronic Lymphocytic Leukemia prevention 2 recruiting NCT04691765
Anakinra in Previously Untreated Chronic Lymphocytic Leukemia Patients treatment 1 unknown_status NCT03971565
Evaluation of the Redox Profiles of Healthy and Pathological B Cells in Patients With Chronic Lymphocytic Leukemia No drug interventions Not Available Not Available unknown_status NCT00143065
Fludarabine, Rituximab, and Alemtuzumab for B-Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma treatment 2 completed NCT06250465
AGMT Austrian CLL (Chronic Lymphocytic Leukemia) Registry No drug interventions Not Available Not Available recruiting NCT03454165
A Study of BNC105P Combined With Ibrutinib treatment 1 completed NCT05154474
Assessment of Sarcopenia at Diagnosis for Patients With Previously Untreated Metastatic Cancer or Hematologic Malignancy No drug interventions Not Available Not Available unknown_status NCT06367374
MRD Guided Sonrotoclax and Zanubrutinib in Newly Diagnosed CLL/SLL treatment 2 not_yet_recruiting NCT04282174
CD34+ Enriched Transplants From HLA-Compatible Patients With Hematologic Malignancies treatment 2 withdrawn NCT00738374
A Study of MabThera (Rituximab) Plus Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia. treatment 2 completed NCT03314974
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders No drug interventions treatment 2 recruiting NCT01346020
Genomic Analysis of Patients With Chronic Lymphocytic Leukemia No drug interventions Not Available Not Available active_not_recruiting NCT05556720
Bringing Optimised COVID-19 Vaccine Schedules To ImmunoCompromised Populations (BOOST-IC): an Adaptive Randomised Controlled Clinical Trial treatment 3 recruiting NCT03893682
A Study of CG-806 in Patients With Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas treatment 1 active_not_recruiting NCT01045382
MSC and HSC Coinfusion in Mismatched Minitransplants No drug interventions treatment 2 terminated NCT06379282
Investigating the Role of Energy Balance Modification on Health Responses in Chronic Lymphocytic Leukaemia No drug interventions supportive_care Not Available recruiting NCT00262782
Fludarabine or Observation in Treating Patients With Stage 0, Stage I, or Stage II Chronic Lymphocytic Leukemia treatment 3 completed NCT00201682
Etanercept and Rituximab in Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma treatment 1 / 2 completed NCT02556931
Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies treatment 2 completed NCT00038831
Allo Transplantation With Mylotarg, Fludarabine and Melphalan for AML, CML and MDS treatment 1 / 2 completed NCT04028531
Understanding Chronic Lymphocytic Leukemia No drug interventions Not Available Not Available recruiting NCT00899431
Nonmyeloablative Stem Cell Transplantation for Chronic Lymphocytic Leukemia (CLL) treatment 2 terminated NCT00889031
Protocol to Obtain Blood Samples for Leukemia Research No drug interventions Not Available Not Available completed NCT00792831
Phase II Study of Histone-deacetylase Inhibitor ITF2357 in Refractory/Relapsed Lymphocytic Leukemia treatment 2 terminated NCT01853631
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN) No drug interventions treatment 1 recruiting NCT00083473
A Pilot Study of Pivanex in Patients With Chronic Lymphocytic Leukemia treatment 2 terminated NCT03328273
A Study of AZD6738 and Acalabrutinib in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) treatment 1 active_not_recruiting NCT00001873
The Role of Cyclosporine in Blood Cell Transplants With T-Cell Add-Back for Blood Cancers No drug interventions treatment 2 completed NCT03191773
A Study of Anti-CD19 CAR-T Cell Immunotherapy for Refractory /Relapsed B Cell Malignancies No drug interventions treatment 1 / 2 unknown_status NCT00431873
A Phase II Study of MGCD0103 (MG-0103) in Patients With Refractory Chronic Lymphocytic Leukemia treatment 2 completed NCT03847727
Bendamustine and Rituximab (BR) as Induction and Maintenance in Relapsed and Refractory Chronic Lymphocytic Leukemia No drug interventions Not Available Not Available unknown_status NCT05739227
Safety and Efficacy of Allogenic CD19-CAR-NK Cells in Treatmenting r/r B-cell Hematologic Malignancies No drug interventions treatment 0 recruiting NCT01496976
Ofatumumab, High Dose Methylprednisolone, Ofatumumab and Lenalidomide Consolidative Therapy for Untreated CLL/SLL treatment 2 active_not_recruiting NCT02860676
Extension Study of UC-961 (Cirmtuzumab) for Patients With Chronic Lymphocytic Leukemia Treated Previously With UC-961 treatment 1 completed NCT00872976
Study of Dasatinib and Bendamustine in Chronic Lymphocytic Leukemia treatment 1 withdrawn NCT00039676
Clinical, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Hematologic Cancer No drug interventions Not Available Not Available active_not_recruiting NCT01125176
Alternating Thalidomide and Lenalidomide Therapy Plus Rituximab (ThRiL) as Initial Treatment for Patients With CLL treatment 2 completed NCT01556776
A Study of Lenalidomide Maintenance for High-risk Patients With CLL Following First-line Therapy treatment 3 completed NCT04502394
Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL treatment 1 / 2 unknown_status NCT05959694
A Clinical Trial on the Safety and Efficacy of TQB3909 Tablets in Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia (CLL) /Small Lymphocytic Lymphoma (SLL) . No drug interventions treatment 1 / 2 recruiting NCT02158091
A Phase 1b/2 Study of IPI-145 Plus FCR in Previously Untreated, Younger Patients With CLL treatment 1 / 2 active_not_recruiting NCT01649791
Lenalidomide as Chemoprevention in Treating Patients With High-Risk, Early-Stage B-Cell Chronic Lymphocytic Leukemia treatment Not Available terminated NCT00586391
CD19 Chimeric Receptor Expressing T Lymphocytes In B-Cell Non Hodgkin's Lymphoma, ALL & CLL treatment 1 active_not_recruiting NCT01572662
Allogeneic Transplantation Using Timed Sequential Busulfan and Fludarabine Conditioning treatment 2 completed NCT01185262
Activity & Safety Study of Lenalidomide & Rituximab as Non-chemotherapy Based Therapy on Chronic Lymphocytic Leukemia treatment 1 completed NCT00810680
Study of Efficacy and Safety of Valproic Acid in Chronic Lymphocytic Leukemia (CLL) treatment Not Available unknown_status NCT02340780
Buparlisib in Patients With Relapsed and Refractory Chronic Lymphocytic Leukemia treatment 2 completed NCT01998880
CLL11: A Study of Rituximab With Chlorambucil or Chlorambucil Alone in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1b) treatment 3 completed NCT03833180
A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001) treatment 1 completed NCT00286780
Phase 2 Safety and Efficacy Study of AT-101 in Combination With Rituximab in Patients With Chronic Lymphocytic Leukemia treatment 2 completed NCT00393380
Study of Parathyroid Hormone Following Sequential Cord Blood Transplantation From an Unrelated Donor prevention 2 terminated NCT05023980
A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) treatment 3 active_not_recruiting NCT02337829
Acalabrutinib in Patients With Relapsed/Refractory and Treatment naïve Deletion 17p CLL/SLL treatment 2 active_not_recruiting NCT04629729
FT819 in Subjects With B-cell Malignancies treatment 1 active_not_recruiting NCT00532129
A Study of MabThera (Rituximab) Plus Chlorambucil in Participants With Chronic Lymphocytic Leukemia. treatment 2 completed NCT04419389
APR-246 in Combination With Acalabrutinib or Venetoclax Based Therapy in Subjects With R/R Non Hodgkin Lymphomas (NHL) No drug interventions treatment 1 / 2 terminated NCT00274989
Bendamustine and Rituximab in Treating Patients With Previously Untreated or Relapsed Chronic Lymphocytic Leukemia No drug interventions treatment 2 completed NCT00073489
A Pilot Study of OSI-461 in Patients With Chronic Lymphocytic Leukemia (CLL) No drug interventions treatment 2 completed NCT02851589
Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma No drug interventions treatment 1 / 2 unknown_status NCT01841489
A Phase 1 Study of Novel GS-9973 Tablet Formulations to Evaluate the Effect of Acid Reducing Agents, Relative Bioavailability, and Food Effect on GS-9973 Pharmacokinetics No drug interventions treatment 1 completed NCT00281892
Fludarabine and Darbepoetin Alfa in Treating Older Patients With Chronic Lymphocytic Leukemia No drug interventions treatment 3 completed NCT05371392
Polymorphism of ITGA4 Gene in Chronic Lymphocytic Leukemia No drug interventions Not Available Not Available not_yet_recruiting NCT03495492
Chronic Lymphocytic Leukemia Responds to Dermal Chelation No drug interventions treatment Not Available unknown_status NCT05020392
Autologous Cells Derived Anti-CD19 CAR-Engineered T Cells With Concurrent BTK Inhibitor for B Cell Lymphoma No drug interventions treatment 3 recruiting NCT00709592
Reduced Intensity Total Body Irradiation + Thymoglobulin Followed by Allogeneic PBSCT No drug interventions treatment 2 completed NCT04774744
Effect of Digital Health Coaching Program on Self-efficacy and Patient Reported Outcomes of Patients With Newly Diagnosed Acute Myeloid Leukemia or Chronic Lymphocytic Leukemia No drug interventions supportive_care Not Available completed NCT00593944
Study of MDX-1342 in Patients With Chronic Lymphocytic Leukemia (CLL) No drug interventions treatment 1 completed NCT03438344
Multi-antigen CMV-Modified Vaccinia Ankara Vaccine in Reducing CMV Related Complications in Patients With Blood Cancer Undergoing Donor Stem Cell Transplant No drug interventions supportive_care 2 withdrawn NCT01255644
Antiviral Treatment of Chronic Lymphocytic Leukemia No drug interventions treatment 4 completed NCT03892044
Duvelisib and Nivolumab in Treating Patients With Richter Syndrome or Transformed Follicular Lymphoma No drug interventions treatment 1 completed NCT01399840
Study of BMN 673, a PARP Inhibitor, in Patients With Advanced Hematological Malignancies No drug interventions treatment 1 completed NCT04155840
Bendamustine and Rituximab in Combination With Copanlisib for the Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No drug interventions treatment 2 terminated NCT01558167
A Safety and Efficacy Trial of a Combination of Bendamustine, Rituximab and Lenalidomide in Patients With Chronic Lymphocytic Leukemia No drug interventions treatment 1 / 2 completed NCT03467867
A Study of Venetoclax and Rituximab/Hyaluronidase Human in Relapsed/Refractory CLL No drug interventions treatment 2 active_not_recruiting NCT05145101
Pneumococcal Vaccination in Patients With Chronic Lymphocytic Leukaemia No drug interventions Not Available Not Available unknown_status NCT03734601
Total Body Irradiation +/- Total Lymphoid Irradiation & Anti-Thymocyte Globulin in Non-myeloablative Hematopoietic Cell Transplantation No drug interventions treatment 2 completed NCT01163201
T-Regulatory Cell and CD3 Depleted Double Umbilical Cord Blood Transplantation in Hematologic Malignancies No drug interventions treatment 1 / 2 withdrawn NCT02533401
A Study of Rituximab (MabThera) in Participants With Chronic Lymphocytic Leukemia (CLL) No drug interventions treatment 2 completed NCT00381004
FCR Plus Sargramostim (GM-CSF) as Frontline Therapy for Symptomatic Chronic Lymphocytic Leukemia No drug interventions treatment 2 completed NCT04814004
Clinical Study of CAR-iNKT Cells in the Treatment of Relapsed/Refractory/High-risk B-cell Tumors No drug interventions treatment 1 unknown_status NCT01671904
A Study of Venetoclax in Combination With Bendamustine + Rituximab or Bendamustine + Obinutuzumab in Participants With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia (CLL) No drug interventions treatment 1 completed NCT03676504
Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR No drug interventions treatment 1 / 2 recruiting NCT04771572
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL. No drug interventions treatment 1 recruiting NCT04722172
A Study on Limiting Treatment Time With Acalabrutinib Combined With Obinutuzumab in People With CLL or SLL No drug interventions treatment 2 active_not_recruiting NCT04858568
Immune Responses to COVID-19 Vaccination in Lymphoma Patients No drug interventions Not Available Not Available completed NCT05718869
Tafasitamab and Zanubrutinib for the Treatment of Patients With Newly Diagnosed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, TaZA CLL Study No drug interventions treatment 2 recruiting NCT05140369
CLL Therapy Approaches in Russia No drug interventions Not Available Not Available recruiting NCT06475469
Description of the Immune Deficiency in Patients With Untreated Chronic Lymphocytic Leukemia and Search for Predictive Factors of Infectious Risk No drug interventions screening Not Available recruiting NCT01539512
A Randomized, Double-Blind, Placebo-Controlled Study of Idelalisib in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL) No drug interventions treatment 3 completed NCT04679012
Polatuzumab Vedotin in Combination With Chemotherapy in Subjects With Richter's Transformation No drug interventions treatment 2 recruiting NCT00535912
Phase III Study Treatment of CLL B and C No drug interventions treatment 3 completed NCT01352312
Combination of Pentostatin, Bendamustine and Ofatumumab for Treatment of Chronic Lymphocytic Leukemia and Lymphoma No drug interventions treatment 1 terminated NCT05478512
Front-line VenObi Combination Followed by Ven or VenZan Combination in Patients With Residual Disease: a MRD Tailored Treatment for Young Patients With High-risk CLL No drug interventions treatment 2 recruiting NCT01231412
Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant No drug interventions treatment 3 completed NCT01056510
A Study of MabThera Added to Bendamustine or Chlorambucil in Patients With Chronic Lymphocytic Leukemia (MaBLe) No drug interventions treatment 4 completed NCT01271010
A Study of Rituximab in Combination With Fludarabine and Cyclophosphamide in Participants With Chronic Lymphocytic Leukemia and Favorable Somatic Status No drug interventions treatment 4 terminated NCT00254410
FCM-R (Fludarabine, Cyclophosphamide, Mitoxantrone, Rituximab) in Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL) < 70 Years No drug interventions treatment 2 completed NCT02053610
CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 2) No drug interventions treatment 3 completed NCT02475681
Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment naïve CLL No drug interventions treatment 3 active_not_recruiting NCT04059081
A Prospective Cohort of Obinutuzumab and Chlorambucil (GC) Chemotherapy for the Treatment of Elderly Patients With Chronic Lymphocytic Leukemia Including Next- Generation Sequencing (NGS)-Based Assessment No drug interventions treatment 2 unknown_status NCT03737981
Testing The Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia No drug interventions treatment 3 active_not_recruiting NCT04160195
T Cells Expressing Fully-human Anti-CD19 and Anti-CD20 Chimeric Antigen Receptors for Treating B-cell Malignancies and Hodgkin Lymphoma No drug interventions treatment 1 terminated NCT00262795
Fludarabine or Chlorambucil as First-Line Therapy in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia No drug interventions treatment 3 completed NCT00466895
Lenalidomide in Acute Leukemias and Chronic Lymphocytic Leukemia. No drug interventions treatment 1 completed NCT04030195
Dose-escalation Study of Safety of PBCAR20A in Subjects With r/r NHL or r/r CLL/SLL No drug interventions treatment 1 / 2 completed NCT00963495
Study Evaluating the Tolerance and Biological Activity of Oral Clioquinol in Patients With Relapsed or Refractory Hematological Malignancy No drug interventions treatment 1 terminated NCT01090414
An Extension Study for Subjects Who Are Deriving Benefit With Idelalisib (GS-1101; CAL-101) Following Completion of a Prior Idelalisib Study No drug interventions treatment 1 / 2 terminated NCT00131014
Establishing a Tumor Bank in Families With Multiple Lymphoproliferative Malignancies No drug interventions Not Available Not Available recruiting NCT03207555
Ibrutinib as Early Therapy in Chronic Lymphocytic Leukemia (CLL) No drug interventions treatment 2 completed NCT05672355
A Vaccine Booster (GEO-CM04S1) for the Prevention of COVID-19 in Patients With Chronic Lymphocytic Leukemia No drug interventions prevention 2 recruiting NCT04746950
ALICIA (Acalabrutinib in CLL Therapy) No drug interventions Not Available Not Available active_not_recruiting NCT00183950
Study of Noscapine for Patients With Low Grade Non Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia Refractory to Chemotherapy No drug interventions treatment 1 / 2 terminated NCT00946023
Optimized Donor Selection, Nonmyeloablative BMT for B-cell Lymphomas With Post-transplantation Cy and Rituximab No drug interventions treatment 2 terminated NCT00036023
Chemotherapy Related Anemia in Patients With Non-Myeloid Malignancies No drug interventions treatment 2 completed NCT06084923
Outcomes of Unfit Patients With CLL Included in the GIMEMA LLC1114 Trial Who Discontinued Ibrutinib Due to Reasons Other Than Disease Progression No drug interventions Not Available Not Available not_yet_recruiting NCT02846623
Atezolizumab, Obinutuzumab, and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Relapsed or Refractory Richter Syndrome No drug interventions treatment 2 recruiting NCT04704323
CAP-100 for Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia No drug interventions treatment 1 recruiting NCT03534323
Duvelisib and Venetoclax in Relapsed or Refractory CLL or SLL or RS No drug interventions treatment 1 / 2 active_not_recruiting NCT03447808
Daratumumab and Ibrutinib in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia No drug interventions treatment 1 active_not_recruiting NCT00108108
Dose-finding Trial of HCD122 in Patients With Chronic Lymphocytic Leukemia (CLL) That is Relapsed or Non-responsive to Prior Fludaribine Therapy No drug interventions treatment 1 terminated NCT04504708
Dose-Escalation and Dose-Expansion Study of ZX-101A in Patients With Relapsed/Resistant or Refractory Advanced Hematologic Malignancies No drug interventions treatment 1 / 2 terminated NCT00594308
In-Vivo Activated T-Cell Depletion to Prevent GVHD No drug interventions treatment Not Available terminated NCT02952508
Study of Iopofosine I 131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) and Pivotal Expansion in Waldenstrom Macroglobulinemia No drug interventions treatment 2 recruiting NCT02611908
Obinutuzumab With High-dose Ibrutinib for the Treatment of Patients With Chronic Lymphocytic Leukemia With Progressive Disease on Single Agent Ibrutinib. No drug interventions treatment 1 withdrawn NCT04666038
Study of LOXO-305 Versus Investigator's Choice (IdelaR or BR) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) No drug interventions treatment 3 active_not_recruiting NCT00836043
Safety, Effectiveness and Patient Acceptance of the Treatment With MabCampath in Chronic Lymphocytic Leukemia No drug interventions Not Available Not Available terminated NCT04282343
DISCO Application for the Improvement of Financial Outcomes in Patients With Hematologic Cancer No drug interventions health_services_research Not Available completed NCT02029443
ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia No drug interventions treatment 1 / 2 active_not_recruiting NCT00759603
Lenalidomide and Rituximab as Treatment of Chronic Lymphocytic Leukemia No drug interventions treatment 2 completed NCT00285103
SPC2996 in Chronic Lymphocytic Leukaemia No drug interventions treatment 1 / 2 completed NCT00186303
Transplantation for Patients With Chronic Lymphocytic Leukemia No drug interventions treatment Not Available completed NCT04494503
Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL No drug interventions treatment 1 / 2 recruiting NCT00714103
8-Chloro-Adenosine in Chronic Lymphocytic Leukemia No drug interventions treatment 1 completed NCT00086203
Study of Talabostat and Rituximab in Advanced Chronic Lymphocytic Leukemia (CLL) No drug interventions treatment 2 completed NCT02401503
Sequential Regimen of Bendamustine-Debulking Followed by ABT-199 and GA101-Induction and -Maintenance in CLL (CLL2-BAG) No drug interventions treatment 2 active_not_recruiting NCT01611090
A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No drug interventions treatment 3 completed NCT05512390
A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL) No drug interventions treatment 1 recruiting NCT03310190
Study to Describe the Management and the Use of Healthcare Resources in Patients With Chronic Lymphocytic Leukemia (CLL) Initiating Venetoclax in Routine Clinical Practice No drug interventions Not Available Not Available completed NCT02371590
Lenalidomide and Obinutuzumab for Previously Untreated CLL No drug interventions treatment 2 withdrawn NCT02742090
Evaluate the Efficacy and Safety of TGR-1202 in Participants With Chronic Lymphocytic Leukemia Who Are Intolerant to Prior Therapy No drug interventions treatment 2 terminated NCT01659021
Efficacy and Safety of Idelalisib in Combination With Ofatumumab for Previously Treated Chronic Lymphocytic Leukemia No drug interventions treatment 3 terminated NCT04149821
Umbralisib Plus Ublituximab (U2) in Progressive CLL After Novel Therapy No drug interventions treatment 2 terminated NCT01290302
Bioequivalence Trial of Luitpold Azacitidine Versus Vidaza® in Patients With Myelodysplastic Syndrome, Myelofibrosis, Chronic Myeloid Leukemia or Chronic Lymphocytic Leukemia No drug interventions treatment 1 completed NCT01326702
Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors No drug interventions treatment 1 / 2 completed NCT02924402
Study to Evaluate Safety and Tolerability of XmAb13676 (Plamotamab) in Patients With CD20-expressing Hematologic Malignancies No drug interventions treatment 1 active_not_recruiting NCT00749502
A Study of MK4827 in Participants With Advanced Solid Tumors or Hematologic Malignancies (MK-4827-001 AM8) No drug interventions treatment 1 completed NCT02131584
Ruxolitinib Phosphate in Reducing Fatigue in Patients With Chronic Lymphocytic Leukemia No drug interventions supportive_care 2 active_not_recruiting NCT05287984
Zanubrutinib Followed Zanubrutinib Plus FCR / BR in Newly Diagnosed Symptomatic CLL/SLL No drug interventions treatment 2 not_yet_recruiting NCT04978779
A Study to Evaluate VIP152 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia or Richter Syndrome No drug interventions treatment 1 terminated NCT02507479
Thiotepa-based Conditioning for Allogeneic Stem-cell Transplantation (SCT) in Lymphoid Malignancies No drug interventions treatment 2 unknown_status NCT03128879
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL No drug interventions treatment 2 recruiting NCT01392079
Subcutaneous Alemtuzumab Combined With Oral Dexamethasone, Followed by Alemtuzumab Maintenance or Allo-SCT in CLL With 17p- or Refractory to Fludarabine No drug interventions treatment 2 completed NCT01173679
Dasatinib With Fludarabine and Rituximab in Relapsed and Refractory CLL and SLL No drug interventions treatment 2 terminated NCT02320487
A Study of Obinutuzumab + Bendamustine (BG) in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL) No drug interventions treatment 2 completed NCT01973387
A Study of PCI-32765 (Ibrutinib) Versus Rituximab in Relapsed or Refractory Chronic Leukemia/Lymphoma No drug interventions treatment 3 completed NCT02506933
Multi-antigen CMV-MVA Triplex Vaccine in Reducing CMV Complications in Patients Previously Infected With CMV and Undergoing Donor Hematopoietic Cell Transplant No drug interventions supportive_care 2 active_not_recruiting NCT00428233
Banking of Chronic Lymphocytic Leukemia Tumor Cells for Vaccine Generation No drug interventions treatment 1 completed NCT02640833
A Study of Duvelisib and Venetoclax in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Indolent or Aggressive Non-Hodgkin Lymphoma, Who Have Not Previously Received a Bcl-2 or PI3K Inhibitor No drug interventions treatment 1 withdrawn NCT03870633
Assessment of Financial Difficulty in Participants With Chronic Lymphocytic Leukemia and Multiple Myeloma No drug interventions Not Available Not Available completed NCT00974233
Study of Bendamustine/Rituxan Induction Chemotherapy With Revlimid Maintenance for Relapsed/Refractory CLL and SLL No drug interventions treatment 2 completed NCT05797233
Trial of Anti-CD19 and Anti-CD20 Bicistronic Chimeric Antigen Receptor T Cells for Treating B-Cell Malignancies No drug interventions treatment 1 active_not_recruiting NCT05879133
HEALTH4CLL2: A Randomized Waitlist Control Trial of Behavioral Interventions in Patients With Chronic Lymphocytic Leukemia No drug interventions supportive_care Not Available recruiting NCT05183854
Pneumococcal Pneumonia Vaccine Series (PCV20 and PPSV23) in Patients With Chronic Lymphocytic Leukemia Associated Immunodeficiency, PROTECT CLL Trial No drug interventions treatment 2 recruiting NCT04505254
Acalabrutinib and Obinutuzumab for the Treatment of Chronic Lymphocytic Leukemia No drug interventions treatment 2 recruiting NCT00438854
Dasatinib in Relapsed Chronic Lymphocytic Leukemia No drug interventions treatment 2 completed NCT05624554
A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008) No drug interventions treatment 3 recruiting NCT04094051
Observational Study of CLL/SLL Treatment and Ibrutinib Treatment of CLL/SLL in Routine Clinical Practice No drug interventions Not Available Not Available unknown_status NCT05971251
Addition of Loncastuximab Tesirine to Acalbrutinib , Chronic Lymphocytic Leukemia No drug interventions treatment 1 recruiting NCT01455051
Ofatumumab as Part of Reduced Intensity Conditioning (RIC) Regimen for Patients With High Risk Chronic Lymphocytic Leukemia (CLL) Undergoing Allogeneic Hematopoietic Cell Transplantation No drug interventions treatment 2 completed NCT02950051
Standard Chemoimmunotherapy (FCR/BR) Versus Rituximab + Venetoclax (RVe) Versus Obinutuzumab (GA101) + Venetoclax (GVe) Versus Obinutuzumab + Ibrutinib + Venetoclax (GIVe) in Fit Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without Del(17p) or TP53 Mutation No drug interventions treatment 3 completed NCT00899353
Prevention of Disease Progression in Early Stage Indolent B Cell Malignancies. (SMM) No drug interventions treatment 2 terminated NCT01644253
Phase 1b Safety and Efficacy Study of TRU-016 No drug interventions treatment 1 terminated NCT01600053
Revlimid® as Consolidation Treatment Chronic Lymphocytic Leukemia No drug interventions treatment 2 terminated NCT05972577
Geriatric Optimization Plan to Improve Survival in Older Adult Allogeneic Hematopoietic Cell Transplant Candidates, OTIS Study No drug interventions supportive_care Not Available active_not_recruiting NCT04060277
Triplex Vaccine in Preventing CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplantation No drug interventions supportive_care 2 active_not_recruiting NCT01659047
A Phase 2, Single-Arm, Open-Label Study Evaluating the Efficacy and Safety of Single Agent GS 1101 (CAL 101) as Therapy for Previously Treated Chronic Lymphocytic Leukemia No drug interventions treatment 2 withdrawn NCT00587847
Campath Maintenance in Chronic Lymphocytic Leukemia No drug interventions treatment Not Available terminated NCT01300247
A Study of Obinutuzumab (GA101; RO5072759) in Combination With Chemotherapy in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL) (GALTON) No drug interventions treatment 1 completed NCT00931645
Autologous Stem Cell Transplantation in Chronic Lymphocytic Leukemia No drug interventions treatment 3 completed NCT03633045
Observational Study of Ibrutinib Use in CLL No drug interventions Not Available Not Available unknown_status NCT01350245
Bone Marrow Transplantation of Patients in Remission Using Partially Matched Relative Donor No drug interventions treatment 2 completed NCT01848145
Rapid Infusion of Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia No drug interventions treatment 2 completed NCT01527045
Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies No drug interventions prevention 2 completed NCT02242045
Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Japanese Participants With Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphomas (iNHL) or Chronic Lymphocytic Leukemia (CLL) No drug interventions treatment 1 completed NCT04660045
Early Intervention With Acalabrutinib in Patients With High Risk CLL No drug interventions treatment 2 withdrawn NCT00143845
Study of Low-Intensity Conditioning for Allogeneic Stem Cell Transplant No drug interventions treatment 2 completed NCT06205498
Acalabrutinib Real World Italian obSErvational Study -ARISE No drug interventions Not Available Not Available recruiting NCT02991898
Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme Malignancies No drug interventions treatment 2 terminated NCT00759798
Identifying Prognostic Factors in Frontline FCR for Patients With Chronic Lymphocytic Leukemia (CLL) No drug interventions treatment 2 completed NCT04016805
Study to Assess the Efficacy and Safety of Ublituximab and Umbralisib in Participants With Chronic Lymphocytic Leukemia (CLL) Currently Treated With Ibrutinib, Acalabrutinib or Venetoclax No drug interventions treatment 2 terminated NCT02756897
Venetoclax and Ibrutinib in Treating Patients With Chronic or Small Lymphocytic Leukemia No drug interventions treatment 2 active_not_recruiting NCT05458297
A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006) No drug interventions treatment 2 recruiting NCT02316197
Clinical Phase I Study Investigating MSC2490484A, an Inhibitor of a DNA-dependent Protein Kinase, in Advanced Solid Tumors or Chronic Lymphocytic Leukemia No drug interventions treatment 1 completed NCT02481297
Lirilumab With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) Patients No drug interventions treatment 2 completed NCT02320383
CLLR3: Bendamustine + GA101 (BG) in Relapsed or Refractory CLL Followed by GA101 Maintenance for Responding Patients No drug interventions treatment 2 unknown_status NCT00281983
Fludarabine and Cyclophosphamide in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Chronic Lymphocytic Leukemia or Waldenstrom's Macroglobulinemia No drug interventions treatment 1 / 2 completed NCT02910583
Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (CLL/SLL) No drug interventions treatment 2 completed NCT02819583
CAR-T Cell Immunotherapy in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma No drug interventions treatment 1 / 2 unknown_status NCT01696461
A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor No drug interventions treatment 2 completed NCT00558961
Dose Escalation Study of Gleevec and Chlorambucil in Previously Treated Chronic Lymphocytic Leukemia Patients No drug interventions treatment 1 / 2 terminated NCT03836261
Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL No drug interventions treatment 3 active_not_recruiting NCT01010061
CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1a) No drug interventions treatment 3 completed NCT02013128
Ublituximab + Ibrutinib in Select B-cell Malignancies No drug interventions treatment 1 / 2 completed NCT05618028
Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets No drug interventions treatment 1 recruiting NCT00772811
Using Fludarabine and Melphalan Conditioning Regimen for CLL,Lymphoma,Multiple Myeloma No drug interventions treatment 2 completed NCT02756611
A Study to Evaluate the Efficacy of Venetoclax Monotherapy in Relapsed/Refractory Participants With Chronic Lymphocytic Leukemia (CLL) No drug interventions treatment 3 completed NCT06396611
Exercise as Intervention in Chronic Lymphocytic Leukemia No drug interventions treatment Not Available recruiting NCT02612311
Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Participants With Untreated and Previously Treated Chronic Lymphocytic Leukemia No drug interventions treatment 3 terminated NCT02717611
A Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy No drug interventions treatment 2 active_not_recruiting NCT01629511
Allogeneic Stem Cell Transplant for CLL No drug interventions treatment 1 / 2 terminated NCT02042911
Efficacy and Safety Study of SyB L-0501 for Patients With Chronic Lymphocytic Leukemia No drug interventions treatment 2 completed NCT04282811
Observational Study Relapsed or Refractory Chronic Lymphocytic Leukemia Venetoclax-based Regimens Outside Clinical Trials in Italy No drug interventions Not Available Not Available recruiting NCT03422393
Venetoclax With High-dose Ibrutinib for CLL Progressing on Single Agent Ibrutinib No drug interventions treatment 1 active_not_recruiting NCT01224093
An Observational Study on the Safety Profile of MabThera/Rituxan (Rituximab) in Combination With Chemotherapy in Patients With B Cell-lineage Chronic Lymphocytic Leukaemia (MABERYC) No drug interventions Not Available Not Available completed NCT01295593
Low Dose CdA Combined With Valproic Acid (VPA) in Previously Treated B-cell Chronic Lymphocytic Leukemia(B-CLL) No drug interventions treatment 1 / 2 unknown_status NCT00022971
Combination Antibody Therapy for Relapsed Lymphoma and Chronic Lymphocytic Leukemia No drug interventions treatment 1 terminated NCT02801578
A Study of Different Doses of Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL) No drug interventions treatment 2 / 3 completed NCT00868478
The Humanized Monoclonal Antibody Milatuzumab for Refractory Chronic Lymphocytic Leukemia (CLL) No drug interventions treatment 1 / 2 unknown_status NCT00413478
5-Azacytidine (Azacytidine; Vidaza) in Chronic Lymphocytic Leukemia No drug interventions treatment 2 terminated NCT05521178
Cardiotoxicities in Patients Receiving BTKi No drug interventions Not Available Not Available withdrawn NCT01980888
Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab in Adults With Previously Untreated Chronic Lymphocytic Leukemia No drug interventions treatment 3 terminated NCT00046488
Safety and Efficacy of IDEC-152 in the Treatment of Chronic Lymphocytic Leukemia (CLL) No drug interventions Not Available 1 completed NCT00949988
A Study of Dasatinib and Rituximab for Relapsed/Refractory Chronic Lymphocytic Leukemia No drug interventions treatment 1 / 2 terminated NCT03204188
Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma No drug interventions treatment 2 active_not_recruiting NCT04904588
HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide No drug interventions treatment 2 recruiting NCT01728207
Phase I Dose Escalation Study of IMMU-114 in Relapsed or Refractory NHL and CLL No drug interventions treatment 1 terminated NCT02581007
Reduced Intensity Conditioning Transplant Using Haploidentical Donors No drug interventions treatment 2 completed NCT03088709
Haploidentical Stem Cell Transplantation Using Post-Transplant Cyclophosphamide No drug interventions prevention 2 terminated NCT01787409
Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D Insufficiency No drug interventions treatment Not Available recruiting NCT05405309
RP-3500 and Olaparib in DNA Damage Repair Pathway Deficient Relapsed/Refractory Chronic Lymphocytic Leukemia No drug interventions treatment 1 / 2 recruiting NCT02629809
Ibrutinib, Fludarabine Phosphate, Cyclophosphamide, and Obinutuzumab in Treating Patients With Chronic Lymphocytic Leukemia No drug interventions treatment 2 active_not_recruiting NCT05281809
Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia No drug interventions treatment 2 recruiting NCT02301156
Ublituximab in Combination With Ibrutinib Versus Ibrutinib Alone in Participants With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL) No drug interventions treatment 3 completed NCT00058656
Autologous T Cell Immunotherapy for Chronic Lymphocytic Leukemia (CLL) Patients No drug interventions treatment 1 / 2 completed NCT05107856
PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies No drug interventions treatment 1 terminated NCT00109356
Study of AQ4N in Patients With Non Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, or Small Lymphocytic Leukemia No drug interventions treatment 1 / 2 unknown_status NCT05928156
Multiple Myeloma/Chronic Lymphocytic Leukemia Coach RCT No drug interventions supportive_care Not Available completed NCT03370185
Phase 2 Study of Duvelisib in Previously Treated Patients With Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma No drug interventions treatment 2 withdrawn NCT02006485
Ublituximab in Combination With TGR-1202 +/- Ibrutinib or Bendamustine in Patients With B-cell Malignancies No drug interventions treatment 1 completed NCT06544785
Zanubrutinib With Obinutuzumab in Untreated Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No drug interventions treatment 2 not_yet_recruiting NCT01951885
Tac, Mini-MTX, MMF Versus Tac, MTX for GVHD Prevention No drug interventions supportive_care 3 completed NCT06001385
HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis No drug interventions treatment 2 recruiting NCT01051115
Dasatinib Combination for Chronic Lymphocytic Leukemia(CLL) With Refractory Disease No drug interventions treatment 2 unknown_status NCT00038415
A Phase I/II Trial of Idiotypic Vaccination for Chronic Lymphocytic Leukemia Using a Genetic Approach No drug interventions treatment 1 / 2 terminated NCT01395615
An Observational Study on The Health Related Quality of Life in Patients With Chronic Lymphocytic Leukaemia No drug interventions Not Available Not Available completed NCT00880815
Fludarabine, Bendamustine, and Rituximab in Treating Participants With Lymphoid Cancers Undergoing Stem Cell Transplant No drug interventions treatment 1 completed NCT01534715
IMGN529 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia No drug interventions treatment 1 completed NCT02530515
Ex Vivo-activated Autologous Lymph Node Lymphocytes in Treating Patients With Chronic Lymphocytic Leukemia No drug interventions treatment 2 completed NCT00275015
Cyclophosphamide and Total Body Irradiation in Treating Patients Who Are Undergoing an Autologous Peripheral Stem Cell Transplant For Chronic Lymphocytic Leukemia No drug interventions treatment 2 completed NCT00727415
Lenalidomide, Fludarabine & Cyclophosphamide in Advanced Chronic Lymphocytic Leukemia Not Responding to Therapy No drug interventions treatment 1 / 2 completed NCT02208037
Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203) No drug interventions prevention 2 completed NCT03263637
Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological Malignancies No drug interventions treatment 1 completed NCT00001637
Immunosuppressive Preparation Followed by Blood Cell Transplant for the Treatment of Blood Cancers in Older Adults No drug interventions treatment 2 completed NCT01069432
Protocol to Obtain Blood for Discovery of Novel Biomarkers and Potential Therapeutic Targets in Chronic Lymphocytic Leukemia No drug interventions Not Available Not Available withdrawn NCT01423032
Bendamustine Versus Fludarabine in Chronic Lymphocytic Leukemia (CLL) No drug interventions treatment 2 / 3 completed NCT01445132
Adoptive Cell Therapy for B-Cell Cancers in Patients After Stem Cell Transplantation No drug interventions treatment 1 completed NCT00100152
A Notch Signalling Pathway Inhibitor for Patients With T-cell Acute Lymphoblastic Leukemia/Lymphoma (ALL)(0752-013) No drug interventions treatment 1 terminated NCT04950452
Exercise Training to Promote Resilience to Chronic Lymphocytic Leukemia No drug interventions health_services_research Not Available completed NCT02100852
TGR-1202, a PI3K Delta Inhibitor, in Combination With Obinutuzumab and Chlorambucil in Patients With Chronic Lymphocytic Leukemia (CLL) No drug interventions treatment 1 completed NCT00330252
Weekly Subcutaneous Alemtuzumab and Rituximab for Relapsed CLL No drug interventions treatment 1 completed NCT00145652
Adjuvant I.V. Iron Therapy During Erythropoetin Treatment of Anemic Patients With Lymphoproliferative Disorders. No drug interventions treatment 3 completed NCT04663100
Oral Adherence in Hematological Oncology Agents and Impact on Comorbid Therapy Adherence No drug interventions health_services_research Not Available recruiting NCT04464200
19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers No drug interventions treatment 1 active_not_recruiting NCT00276159
Study of Immune Response Modifier in the Treatment of Hematologic Malignancies No drug interventions treatment 2 terminated NCT04980859
Zebutinib Combined With Immunochemotherapy in the Treat of Newly Treated CLL Patients Without 17p-/TP53 Mutation No drug interventions treatment 3 not_yet_recruiting NCT06136559
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011) No drug interventions treatment 3 recruiting NCT00267059
Lenalidomide (Revlimid) in Chronic Lymphocytic Leukemia (CLL) No drug interventions treatment 2 completed NCT01871675
Study of IPI-145 in Combination With Rituximab or Bendamustine/Rituximab in Hematologic Malignancies No drug interventions treatment 1 completed NCT06524375
A Study to Evaluate the Effect of Venetoclax on Participants Receiving a Covalent Bruton's Tyrosine Kinase Inhibitor (cBTKi) for First-Line Chronic Lymphocytic Leukemia (1L CLL) to Achieve Deep Durable Remissions to Allow Off-Treatment Period No drug interventions treatment 2 recruiting NCT01251575
Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant No drug interventions treatment 2 completed NCT01980875
Efficacy and Safety of Idelalisib in Combination With Obinutuzumab Compared to Chlorambucil in Combination With Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia No drug interventions treatment 3 terminated NCT01796470
Entospletinib in Combination With Idelalisib in Adults With Relapsed or Refractory Hematologic Malignancies No drug interventions treatment 2 terminated NCT00569842
Investigation of the Cylex® ImmuKnow® Assay No drug interventions Not Available Not Available completed NCT00270049
Epoetin Alfa for the Treatment of Anemia Resulting From Chronic Lymphocytic Leukemia No drug interventions treatment 2 completed NCT00289549
Study of Forodesine Hydrochloride in Patients With Advanced, Fludarabine-refractory Chronic Lymphocytic Leukemia (CLL) No drug interventions treatment 2 completed NCT01290549
A Study of Escalating Doses of Polatuzumab Vedotin in Participants With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma and Chronic Lymphocytic Leukemia and Polatuzumab Vedotin in Combination With Rituximab in Participants With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma No drug interventions treatment 1 completed NCT03913949
A Study to Evaluate the Safety,PK and PD of APG-2575 in Patients With Hematologic Malignancies No drug interventions treatment 1 active_not_recruiting NCT00718549
A Study to Assess the Effect of Maintenance Treatment With Rituximab Versus No Treatment in Participants With Progressive B-Cell Chronic Lymphocytic Leukemia (CLL) No drug interventions treatment 3 completed NCT01962636
Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases No drug interventions treatment Not Available recruiting NCT00596336
Study of Immune Responses to Influenza Vaccination With or Without Imiquimod Application in Untreated CLL Patients No drug interventions prevention 2 terminated NCT01030536
Safety Study of CAT-8015 to Treat Advanced B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia (NHL or CLL) No drug interventions treatment 1 / 2 completed NCT00151736
Safety and Efficacy of SDX-101 (R-Etodolac) in Combination With Chlorambucil, and That of Chlorambucil Alone, in Patients With Chronic Lymphocytic Leukemia (CLL) No drug interventions treatment 2 terminated NCT02993536
Clonal Evolution of B Cells in High-risk CLL After Idelalisib-rituximab No drug interventions Not Available Not Available withdrawn NCT02825836
Phase I/II, FIH, Dose Escalation Trial of TL-895 and Expansion of TL-895 Monotherapy and Combination Therapy With Navtemadlin in Tx-Naïve and R/R CLL/SLL Subjects No drug interventions treatment 1 / 2 active_not_recruiting NCT01030913
B-type Chronic Lymphocytic Leukemia (B-CLL) Subgroups: Maturation Stage and Gene Expression No drug interventions Not Available Not Available completed NCT06211413
Hypertension and Arrhythmias in CLL Patients Treated With BTK Inhibitors No drug interventions Not Available Not Available enrolling_by_invitation NCT01410513
Study Combining SAR245409 With Rituximab or Bendamustine Plus Rituximab in Patients With Indolent Lymphoma, Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia No drug interventions treatment 1 completed NCT02537613
A Study of Ibrutinib + Obinutuzumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia No drug interventions treatment 1 active_not_recruiting NCT00131313
Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia. No drug interventions treatment 4 unknown_status NCT04578613
ICP-022 Versus Chlorambucil Combined With Rituximab in the Treatment of Untreated CLL/SLL No drug interventions treatment 3 recruiting NCT02863718
Ibrutinib in Previously Untreated Binet Stage A Chronic Lymphocytic Leukemia With Risk of Disease Progression No drug interventions treatment 3 completed NCT06037018
Safety Study of CC312 in Adult Patients With Relapsed/Refractory CD19 Positive B-cell Hematologic Malignancies No drug interventions treatment 1 recruiting NCT04163718
TGR-1202 (Umbralisib) in Treatment Naïve Patients With Chronic Lymphocytic Leukemia (CLL) No drug interventions treatment 2 terminated NCT05544019
Study of SGR-1505 in Mature B-Cell Neoplasms No drug interventions treatment 1 recruiting NCT06428019
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) No drug interventions treatment 3 recruiting NCT03375619
Long-term Follow-up Study of Patients Receiving CAR-T Cells No drug interventions Not Available Not Available recruiting NCT02689141
Sequential Regimen of Bendamustin-Debulking Followed by Ofatumumab and Ibrutinib in CLL Patients (CLL2-BIO) No drug interventions treatment 2 completed NCT00280241
Protocol for the Treatment of Patients With Previously Untreated Chronic Lymphocytic Leukemia No drug interventions treatment 2 completed NCT05410041
Anti-CD19 CAR-Engineered NK Cells in the Treatment of Relapsed/Refractory B-cell Malignancies No drug interventions treatment 1 unknown_status NCT01625741
Phase II Study of High-Dose Rituximab in High-Risk Chronic Lymphocytic Leukemia Patients in Suboptimal Response After Induction Immunochemotherapy No drug interventions treatment 2 terminated NCT03528941
The Incidence of Hepatitis B Reactivations in Patients Affected by Chronic Lymphocytic Leukemia With Ibrutinib No drug interventions Not Available Not Available completed NCT04312841
Letermovir for the Prevention of Cytomegalovirus Reactivation in Patients With Hematological Malignancies Treated With Alemtuzumab No drug interventions treatment 2 active_not_recruiting NCT00536341
Fludarabine, Rituximab, and Lenalidomide in Minimally Treated/Untreated Patients With Chronic Lymphocytic Leukemia (CLL) No drug interventions treatment 1 / 2 completed NCT04342117
Observational Trial of Real-World Treatment Utilization and Effectiveness of PI3K-inhibitors in CLL/SLL and FL No drug interventions Not Available Not Available terminated NCT02827617
Identification of Biomarkers That Are Predictive of Early Ibrutinib Treatment Failure in High Risk TP53 Mutated Chronic Lymphocytic Leukemia No drug interventions Not Available Not Available active_not_recruiting NCT02013817
CHAIROS Study A Study of MabThera/Rituxan (Rituximab) Maintenance Therapy in Patients With B-Cell Chronic Lymphocytic Leukemia (CLL) Naive to Chemotherapy No drug interventions treatment 2 completed NCT00078234
Genasense® (Oblimersen Sodium), Fludarabine, and Rituximab in Subjects With Chronic Lymphocytic Leukemia No drug interventions treatment 1 / 2 completed NCT01118234
Rituximab Versus Observation as Maintenance Therapy in Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) No drug interventions treatment 3 completed NCT02915224
A Study of Obinutuzumab Evaluating Efficacy, Safety and Cost of Disease Management in Participants With Chronic Lymphocytic Leukemia and Comorbidities No drug interventions Not Available Not Available completed NCT02109224
Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection No drug interventions treatment 1 terminated NCT00562224
Study of the Safety and Tolerability of Oral Capsule Form of PCI-24781 in Advanced Cancer Patients No drug interventions treatment 1 completed NCT03436524
A Prognostic Tool for Early Stage CLL No drug interventions Not Available Not Available completed NCT00849524
Study of Repeat Intranodal Injection of Memgen's Cancer Vaccine, Ad-ISF35, in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) No drug interventions treatment 2 terminated NCT02557516
Combination Study of IPH2201 (Monalizumab) With Ibrutinib in Relapsed, Refractory or Previously Untreated CLL No drug interventions treatment 1 / 2 terminated NCT02461316
Rituximab in Combination With Fludarabine and Cyclophosphamide in Patients With Chronic Lymphocytic Leukemia No drug interventions Not Available Not Available completed NCT02900716
Safety Study of BTK Inhibitor, DTRMWXHS-12, Used Singly or in Combination, in CLL and B-cell Lymphomas No drug interventions treatment 1 completed NCT01444716
Ofatumumab as Front-Line Therapy in Treating Elderly Participants With Chronic Lymphocytic Leukemia No drug interventions treatment 2 completed NCT00514696
Study of the Safety of GCS-100 in Subjects With Chronic Lymphocytic Leukemia No drug interventions treatment 2 completed NCT02477696
Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL) No drug interventions treatment 3 active_not_recruiting NCT05943496
Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma No drug interventions treatment 1 recruiting NCT00071396
Campath-1H Plus Rituximab for CD52- and CD20- Positive Refractory or Relapsed Chronic Lymphoid Disorders No drug interventions treatment 2 completed NCT01021358
A Study to Assess the Effect of Ketoconazole on the Metabolism of ABT-263 (Navitoclax). No drug interventions treatment 1 completed NCT00103558
Lumiliximab in Combination With FCR in Subjects With Relapsed Chronic Lymphocytic Leukemia (CLL) No drug interventions treatment 1 / 2 completed NCT00481858
Kinetic Biomarker for Chronic Lymphocytic Leukemia Prognosis No drug interventions Not Available Not Available completed NCT01181258
Penostatin, Rituximab and Ontak and Allogeneic Natural Killer (NK) Cells for Refractory Lymphoid Malignancies No drug interventions treatment 2 completed NCT03545035
Efficacy and Safety in Patients With Chronic Lymphocytic Leukemia (CLL) Treated With Idelalisib and Rituximab in the Clinical Practice: a GIMEMA-ERIC Study No drug interventions Not Available Not Available completed NCT04754035
Clinical Study With Ibrutinib and Venetoclax for Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia No drug interventions treatment 2 active_not_recruiting NCT05643235
Implanted Loop Recorders for Detection and Management of Arrhythmia With Bruton Tyrosine Kinase Inhibitors No drug interventions other Not Available recruiting NCT00274963
Bendamustine and Mitoxantrone in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia No drug interventions treatment 2 completed NCT04684563
huCART19-IL18 in NHL/CLL Patients No drug interventions treatment 1 recruiting NCT01681563
Trial of Pentostatin Plus Cyclophosphamide With Ofatumumab (PCO) in Older Patients With Chronic Lymphocytic Leukemia No drug interventions treatment 2 completed NCT01889186
A Study of the Efficacy of ABT-199 in Subjects With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia With the 17p Deletion No drug interventions treatment 2 completed NCT01283386
A Study to Compare Mabthera (Rituximab), Fludarabine and Cyclophosphamide to Mabthera and Chlorambucil in Participants With Chronic Lymphocytic Leukemia and Unfavorable Somatic Status No drug interventions treatment 4 terminated NCT00772486
A Phase Ib Study of ISF35 in Combination With Chemotherapy (FCR) in Subjects With Relapsed, Refractory, and/or 17p- CLL No drug interventions treatment 1 completed NCT00499239
A Trial of GS-9219 in Chronic Lymphocytic Leukemia (CLL), Non-Hodgkin's Lymphoma (NHL) or Multiple Myeloma (MM) No drug interventions treatment 1 / 2 terminated NCT00769522
FCR or BR in Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia No drug interventions treatment 3 completed NCT02004522
A Phase 3 Study of Duvelisib Versus Ofatumumab in Patients With Relapsed or Refractory CLL/SLL (DUO) No drug interventions treatment 3 completed NCT06466122
Pirtobrutinib (LOXO-305) and Venetoclax for the Treatment of Patients With CLL or SLL Resistant to Covalent BTKi No drug interventions treatment 2 recruiting NCT04245722
FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies No drug interventions treatment 1 terminated NCT02339922
Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma No drug interventions treatment 2 active_not_recruiting NCT02414022
Economic Analysis of Alliance A041202 CLL Study No drug interventions Not Available Not Available active_not_recruiting NCT03492125
A Study Of The Selective PKC-β Inhibitor MS- 553 No drug interventions treatment 1 / 2 terminated NCT02292225
Duvelisib With Obinutuzumab in Patients With CLL/SLL Previously Treated With a BTKi (SYNCHRONY) No drug interventions treatment 1 terminated NCT03801525
Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and Venetoclax Compared to Ublituximab in Combination With Umbralisib in Subjects With CLL (ULTRA-V) No drug interventions treatment 2 / 3 terminated NCT02071225
A Study Evaluating the Efficacy of Obinutuzumab and Bendamustine Treatment in Participants With Refractory or Relapsed Chronic Lymphocytic Leukemia No drug interventions treatment 2 completed NCT00038025
A Study Of Deoxycoformycin(DCF)/Pentostatin In Lymphoid Malignancies No drug interventions treatment 2 completed NCT04666025
SARS-CoV-2 Donor-Recipient Immunity Transfer No drug interventions Not Available Not Available completed NCT00001830
Donor Th2 Cells to Prevent Graft-Versus-Host Disease in Bone Marrow Transplants No drug interventions treatment 1 completed NCT01028430
B Cell Repertoires in Chronic Lymphocytic Leukemia and Aging No drug interventions Not Available Not Available completed NCT00442130
Reduced Intensity Stem Cell Transplantation for Chronic Lymphocytic Leukemia Followed by Vaccination No drug interventions treatment 1 completed NCT01088048
Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia No drug interventions treatment 1 completed NCT02200848
Phase I Study of Lenalidomide, Rituximab and Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) No drug interventions treatment 1 terminated NCT02251548
A Phase II Study of Ibrutinib Plus FCR in Previously Untreated, Younger Patients With Chronic Lymphocytic Leukemia No drug interventions treatment 2 active_not_recruiting NCT02677948
Multicenter Study of Pacritinib Combined With Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) No drug interventions treatment 1 / 2 withdrawn NCT00276848
Fludarabine With or Without Cyclophosphamide in Treating Patients With Advanced Chronic Lymphocytic Leukemia No drug interventions treatment 3 completed NCT00873457
Perifosine in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma No drug interventions treatment 2 completed NCT00850057
Pharmacodynamic (PD) Study of Intranodal Adenovirus-CD154 (Ad-ISF35) in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) No drug interventions treatment 1 completed NCT01393366
Facing Obstacles to RDI (Relative Dose Intensity) Through Telephone Intervention Strategy No drug interventions supportive_care Not Available completed NCT00800566
Oral Clofarabine in Chronic Lymphocytic Leukemia (CLL) No drug interventions treatment 1 withdrawn NCT02758665
Trial of Ibrutinib Plus Venetoclax Plus Obinutuzumab in Patients With CLL No drug interventions treatment 2 completed NCT04952974
B-cell Chronic Lymphoid Malignancies Markers No drug interventions Not Available Not Available unknown_status NCT02264574
A Multi-Center Study of Ibrutinib in Combination With Obinutuzumab Versus Chlorambucil in Combination With Obinutuzumab in Patients With Treatment naïve Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) No drug interventions treatment 3 completed NCT06043674
A Ph 2 Study of Glofitamab Alone or in Combination With Polatuzumab Vedotin or Atezolizumab in Richter's Transformation No drug interventions treatment 2 recruiting NCT05028374
COVID-19 VAX Booster Dosing in Patients With Hematologic Malignancies No drug interventions treatment 2 completed NCT04616274
Pharmacokinetics of Venetoclax in Patients With Chronic Lymphocytic Leukemia No drug interventions Not Available Not Available recruiting NCT02582320
Clinical-biological Characteristics and Outcome of Chronic Lymphocytic Leukemia Under Ibrutinib-named Patient Program No drug interventions Not Available Not Available completed NCT06291220
A Study Assessing Adverse Event and How Oral ABBV-453 Moves Through the Body in Adult Participants With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) No drug interventions treatment 1 recruiting NCT00794820
Fludarabine, Cyclophosphamide, and Rituximab - High Dose Frontline No drug interventions treatment 2 completed NCT03701282
Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymphocytic Leukemia No drug interventions treatment 3 active_not_recruiting NCT02141282
A Phase 2 Open-Label Study of the Efficacy and Safety of ABT-199 (GDC-0199) in Chronic Lymphocytic Leukemia (CLL) Subjects With Relapse or Refractory to B-Cell Receptor Signaling Pathway Inhibitor Therapy No drug interventions treatment 2 completed NCT03096782
Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma No drug interventions treatment 2 completed NCT02129582
Targeted Marrow Irradiation, Fludarabine Phosphate, and Busulfan Before Donor Progenitor Cell Transplant in Treating Patients With Hematologic Malignancies No drug interventions treatment 1 completed NCT02877082
Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients No drug interventions prevention 2 terminated NCT00828282
High-dose HMG-CoA Inhibitor Simvastatin Relapsed CLL No drug interventions treatment 1 completed NCT00275431
Phase II Safety and Efficacy Study of Single-agent AT-101 in Patients With Relapsed or Refractory B-cell Malignancies No drug interventions treatment 2 completed NCT02445131
Sequential Regimen of Bendamustine-Debulking Followed by CAL-101 and GA101-Induction and -Maintenance in CLL (CLL2-BCG) No drug interventions treatment 2 completed NCT02034227
Safety, Tolerability Study of SG2000 in the Treatment of Advanced Chronic Lymphocytic Leukemia and Acute Myeloid Leukemia No drug interventions treatment 1 / 2 terminated NCT01650727
A Study of Dinaciclib in Combination With Rituximab in Participants With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (P07974) No drug interventions treatment 1 completed NCT00674427
Trial of Donor Lymphocyte Infusion (DLI) and Activated DLI Following Relapse After Allogeneic Stem Cell Transplant No drug interventions treatment 1 terminated NCT03529227
Gazyva Infusion Reaction Investigation No drug interventions Not Available Not Available recruiting NCT05465876
Passive Antibodies Against COVID-19 With EVUSHELD in Vaccine Non-responsive CLL No drug interventions treatment 2 withdrawn NCT01515176
Ofatumumab and Dinaciclib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-Cell Prolymphocytic Leukemia No drug interventions treatment 1 / 2 completed NCT03501576
Evaluation of Human Immune Responses Vaccination in Patients With Lymphoma No drug interventions Not Available Not Available recruiting NCT00801060
Evaluation of Safety and Efficacy of Fludarabine, Cyclophosphamide, and Rituximab (FCR) +/- Lumiliximab in Subjects With Previously Untreated Chronic Lymphocytic Leukemia (CLL) No drug interventions treatment 2 terminated NCT03480360
Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression No drug interventions treatment 3 active_not_recruiting NCT03280160
Protocol GELLC-7: Ibrutinib Followed by Ibrutinib Consolidation in Combination With Ofatumumab No drug interventions treatment 2 unknown_status NCT04657094
Acalabrutinib for the Treatment of Relapsed or Refractory Autoimmune Hemolytic Anemia in Patients With Chronic Lymphocytic Leukemia No drug interventions treatment 2 active_not_recruiting NCT01011894
Lenalidomide in Patients With Chronic Lymphocytic Leukemia Older Than 65 Years of Age No drug interventions treatment 2 completed NCT02110394
Ribomustin in the First Line Therapy of Chronic Lymphocytic Leukemia No drug interventions Not Available Not Available completed NCT01739491
A Study of Safety and Effectiveness of Bendamustine Hydrochloride in Adult Filipino Patients With Chronic Lymphocytic Leukemia No drug interventions Not Available Not Available withdrawn NCT01539291
Extension Study of Idelalisib in Participants With Chronic Lymphocytic Leukemia (CLL) Who Participated in GS-US-312-0116 (NCT01539512) No drug interventions treatment 3 terminated NCT06059391
CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant No drug interventions treatment 2 recruiting NCT00481091
A Study of ABT-263 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia No drug interventions treatment 1 / 2 completed NCT01930162
Safety and Tolerability of HSC835 in Patients With Hematological Malignancies Undergoing Single Umbilical Cord Blood Transplant No drug interventions basic_science 2 completed NCT06333262
Fixed Duration Pirtobrutinib and Obinutuzumab in Chronic Lymphocytic Leukemia No drug interventions treatment 2 recruiting NCT01488162
An Observational Study of MabThera/Rituxan (Rituximab) in Patients With Relapsing or Refractory Chronic Lymphocytic Leukemia No drug interventions Not Available Not Available completed NCT00571662
Safety and Efficacy of Pentostatin and Low Dose TBI With Allogenic Peripheral Blood Stem Cell Transplant No drug interventions treatment 2 completed NCT03513562
Venetoclax and Ibrutinib in Treating in Participants With Chronic Lymphocytic Leukemia and Ibrutinib Resistance Mutations No drug interventions treatment 2 active_not_recruiting NCT00167180
Post Transplant Donor Lymphocyte Infusion No drug interventions treatment 2 terminated NCT01610180
Eltrombopag for the Treatment of Immune ThrombocytoPenia (ITP) Secondary to Chronic Lymphoproliferative Disorders (LPDs) No drug interventions treatment 2 completed NCT00022880
Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody for Chronic Lymphocytic Leukemia No drug interventions treatment 1 unknown_status NCT03740529
A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL No drug interventions treatment 1 / 2 active_not_recruiting NCT04785989
In Vivo Metabolic Profiling of CLL (Chronic Lymphocytic Leukemia) No drug interventions Not Available Not Available recruiting NCT01799889
Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacodynamics of Entospletinib in Adults With Relapsed or Refractory Hematologic Malignancies No drug interventions treatment 2 terminated NCT01521689
Tolerance and Efficacy of Subcutanous Low Doses Rituximab for CLL Consolidation Treatment No drug interventions treatment 2 unknown_status NCT01685892
A Study of Venetoclax in Combination With Obinutuzumab in Participants With Chronic Lymphocytic Leukemia No drug interventions treatment 1 completed NCT03881592
Real-World Data Study Focused on Chronic Lymphocytic Leukemia (CLL) Patient Treatment Options and Their Effectiveness No drug interventions Not Available Not Available unknown_status NCT04553692
Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants With Relapsed, Refractory, or Newly Diagnosed Cancers No drug interventions treatment 1 active_not_recruiting NCT05197192
A Phase-3-trial of Acalabrutinib, Obinutuzumab & Venetoclax Compared to Obinutuzumab and Venetoclax in Previously Untreated Patients With High Risk CLL No drug interventions treatment 3 recruiting NCT05093192
Mobilising Tumour and Immune Cells Via Exercise in Chronic Lymphocytic Leukaemia No drug interventions basic_science Not Available completed NCT06362044
A Study to Assess Frequency of Undetectable Minimal Residual Disease (uMRD) in Adult Participants With Chronic Lymphocytic Leukemia (CLL) Receiving Oral Venetoclax Tablets ± Intravenously (IV) Infused Rituximab in Routine Clinical Practice in Japan No drug interventions Not Available Not Available recruiting NCT06547944
Zanubrutinib, Obinutuzumab and Lenalidomide in Newly Diagnosed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) No drug interventions treatment 1 active_not_recruiting NCT01072240
An Observational Study on Infusion-related Adverse Events at Administration of MabThera (Rituximab) in Patients With Chronic Lymphocytic Leukemia No drug interventions Not Available Not Available completed NCT03960840
Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, ALL and 1L HR LBCL No drug interventions treatment 1 / 2 recruiting NCT05147467
Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLL No drug interventions treatment 2 recruiting NCT04809467
A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL) No drug interventions treatment 1 / 2 active_not_recruiting NCT00524667
HDAC Inhibitor Valproic Acid as an Effective Therapy for Chronic Lymphocytic Leukemia No drug interventions treatment 2 terminated NCT06416267
Risk and Clinical Consequences of Low Count Monoclonal B-cell Lymphocytosis (LC MBL) No drug interventions Not Available Not Available not_yet_recruiting NCT00076401
A Study of Motexafin Gadolinium for the Treatment of Chronic Lymphocytic Leukemia (CLL) No drug interventions treatment 2 terminated NCT01310101
Ofatumumab Added to Dexamethasone in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia No drug interventions treatment 2 completed NCT00283101
A Safety Study in Patients With Chronic Lymphocytic Leukemia No drug interventions treatment 1 / 2 completed NCT02619604
A Quality Improvement Approach to the Management of Chronic Lymphocytic Leukemia No drug interventions health_services_research Not Available completed NCT01263704
A Study of MabThera/Rituxan (Rituximab) in Combination With Fludarabine And Cyclophosphamide as Primary Therapy in Elderly Patients With Chronic Lymphocytic Leukemia No drug interventions treatment 2 completed NCT04240704
Safety and Preliminary Efficacy of JBH492 Monotherapy in Patients With CLL and NHL No drug interventions treatment 1 active_not_recruiting NCT04843904
Safe Accelerated Venetoclax Escalation in CLL No drug interventions treatment 1 recruiting NCT00290004
Study of Weekly Motexafin Gadolinium (MGd) for Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No drug interventions treatment 1 / 2 completed NCT00504972
Phase I Trial of Anti-CD74 (hLL1) Antibody Therapy in B Cell Malignancies No drug interventions treatment 1 completed NCT02424968
CD8+ Memory T-Cells as Consolidative Therapy After Donor Non-myeloablative Hematopoietic Cell Transplant in Treating Patients With Leukemia or Lymphoma No drug interventions treatment 2 completed NCT01010568
Ofatumumab and Bendamustine for Previously Treated Chronic Lymphocytic Leukemia (CLL) No drug interventions treatment 2 terminated NCT02315768
Ibrutinib in Combination With GA101 (Obinutuzumab) in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients. No drug interventions treatment 1 / 2 active_not_recruiting NCT05099068
Profiling Program of Cancer Patients With Sequential Tumor and Liquid Biopsies (PLANET) No drug interventions diagnostic Not Available recruiting NCT05334069
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection No drug interventions Not Available Not Available recruiting NCT05037669
Programmed Allogeneic CRISPR-edited T Cells Engineered to Express Anti-CD19 Chimeric Antigen Receptor (PACE CART19) in Patients With Relapsed Or Refractory CD19+ Leukemia and Lymphoma No drug interventions treatment 1 withdrawn NCT00683046
T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancies No drug interventions treatment 2 completed NCT00055146
Study of ONTAK in Patients With B-Cell Chronic Lymphocytic Leukemia (CLL) No drug interventions treatment 2 completed NCT00854646
Phase I Study of ON 01910.Na in Refractory Leukemia or Myelodysplastic Syndrome (MDS) No drug interventions treatment 1 completed NCT01724346
Open-label Extension Study in Patients 65 Years or Older With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No drug interventions treatment 3 completed NCT01403246
Chlorambucil + Lenalidomide and Lenalidomide Maintenance in Untreated Elderly With Chronic Lymphocytic Leukemia (CLL) No drug interventions other 1 / 2 terminated NCT04356846
A Phase I Study of LP-108 in Patients With Relapsed or Refractory B-cell Lymphoma No drug interventions treatment 1 recruiting NCT01050946
Hematopoietic Stem Cell Transplantation (HSCT) Using CD34 Selected Mismatched Related Donor and One Umbilical Cord Unit No drug interventions treatment 2 terminated NCT01744912
Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies No drug interventions treatment 1 terminated NCT05336812
Acalabrutinib in Combination With Venetoclax or Obinutuzumab for the Treatment of Treatment-naive Chronic Lymphocytic Leukemia No drug interventions treatment 2 recruiting NCT05694312
Ibrutinib for the Treatment of AIHA in Patients With CLL/SLL or CLL-like MBL No drug interventions treatment 2 recruiting NCT01670812
Trial of FFP+HDMP+Rituximab for Ultra-high Risk Chronic Lymphocytic Leukemia No drug interventions treatment 3 unknown_status NCT03195010
Management of Platelet Transfusion Therapy in Patients With Blood Cancer or Treatment-Induced Thrombocytopenia No drug interventions supportive_care 2 terminated NCT04155710
Study of Autologous Peripheral Blood Lymphocytes in the Treatment of Patients With CLL or SLL No drug interventions treatment 1 / 2 active_not_recruiting NCT01024010
Ofatumumab, Pentostatin, and Cyclophosphamide in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No drug interventions treatment 2 completed NCT02639910
Study to Evaluate Safety and Preliminary Efficacy of Tafasitamab With Idelalisib or Venetoclax in R/R CLL/SLL Patients Pretreated With BTKi No drug interventions treatment 2 completed NCT00416910
Combination Chemotherapy With or Without G-CSF in Treating Patients With Relapsed Chronic Lymphocytic Leukemia No drug interventions treatment 3 terminated NCT01474681
Safety and Tolerability of HSC835 in Patients With Hematological Malignancies No drug interventions treatment 1 / 2 completed NCT00234481
Safety Study of XL844 in Subjects With Chronic Lymphocytic Leukemia No drug interventions treatment 1 terminated NCT00634881
Alemtuzumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia No drug interventions treatment 1 / 2 completed NCT00309881
Combination Chemotherapy and Rituximab in Treating Patients With Chronic Lymphocytic Leukemia (CLL) That Did Not Respond to Fludarabine, CLL With Autoimmune Haemolytic Anemia (AIHA) or Richter's Transformation (RT) No drug interventions treatment 2 completed NCT06125795
A Study to Assess Change in Functioning and Health Related Quality of Life in Adult Participants With Chronic Lymphocytic Leukemia (CLL) Receiving Oral Treatments in Routine Clinical Practice in Spain No drug interventions Not Available Not Available recruiting NCT01569295
Study Evaluating the Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL) (Tugela ) No drug interventions treatment 3 completed NCT05803395
Incidence of Severe COVID-19 Infection in Patients With CLL or B-NHL Who Received Pre-exposure Prophylaxis With Tixagevimab and Cilgavimab in Italy. No drug interventions Not Available Not Available recruiting NCT02892695
PCAR-119 Bridge Immunotherapy Prior to Stem Cell Transplant in Treating Patients With CD19 Positive Leukemia and Lymphoma No drug interventions treatment 1 / 2 unknown_status NCT00093314
HuMax-CD20 in Chronic Lymphocytic Leukemia No drug interventions treatment 1 / 2 withdrawn NCT03153514
Obinutuzumab Containing Conditioning Regimen for Patients With Poor Risk CLL or Richter's Transformation Requiring Allogeneic Stem Cell Transplantation No drug interventions treatment 2 terminated NCT00543114
Dose Escalation Study of Revlimid With Fludarabine-Rituximab for CLL/SLL No drug interventions treatment 1 terminated NCT02258555
Safety, Pharmacodynamics, Pharmacokinetics, and Efficacy of GS-9901 in Adults With Relapsed or Refractory Follicular Lymphoma, Marginal Zone Lymphoma, Chronic Lymphocytic Leukemia, or Small Lymphocytic Lymphoma No drug interventions treatment 1 terminated NCT00636155
EL625 in Persistent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No drug interventions treatment 2 terminated NCT02518555
Ibrutinib as an Immune Modulating Agent for Patients With Asymptomatic, High-risk CLL/SLL Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No drug interventions treatment 2 active_not_recruiting NCT01657955
Bendamustine Hydrochloride Injection for Previously Untreated Chronic Lymphocytic Leukemia No drug interventions treatment 3 unknown_status NCT01760655
Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies No drug interventions treatment 2 completed NCT03019055
Study of CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell No drug interventions treatment 1 completed NCT01002755
Lenalidomide and Ofatumumab in Treating Participants With Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No drug interventions treatment 2 completed NCT00419250
A Dose Escalation Study of Lenalidomide in Relapsed or Refractory B-cell Chronic Lymphocytic Leukemia No drug interventions treatment 1 completed NCT00754650
A Proof of Concept Study of the Safety, Tolerability, and Efficacy of Avastin (Bevacizumab) in Patients With Chemo-naive Chronic Lymphocytic Leukemia No drug interventions treatment 2 completed NCT01110850
Direct Measurement of Leukemic Cell Turnover (Synthesis and Removal) in Patients With Chronic Lymphocytic Leukemia (CLL) Using Deuterated Water No drug interventions Not Available Not Available completed NCT05437250
National Acalabrutinib Observational Study No drug interventions Not Available Not Available active_not_recruiting NCT02456350
Anti-CD19 Chimeric Antigen Receptor (CAR)-Transduced T Cell Therapy for Patients With B Cell Malignancies No drug interventions treatment 1 unknown_status NCT00918723
Vorinostat, Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No drug interventions treatment 1 / 2 completed NCT02593123
Adoptive Immunotherapy in Relapsed Hematological Malignancy: Early GVHD Prophylaxis No drug interventions treatment 2 completed NCT01609023
A Study of Rituximab (MabThera) in Combination With Chemotherapy in Participants With CD20-Positive B-Cell Chronic Lymphocytic Leukemia No drug interventions Not Available Not Available completed NCT02144623
Pretreatment With Valproate Prior to Immunotherapy Targeting Cluster of Differentiation Antigen 20 in Chronic Lymphocytic Leukemia No drug interventions treatment 0 completed NCT04964908
Study to Understand Clinical Characteristics, Treatment Pathway in Chronic Lymphocytic Leukemia No drug interventions Not Available Not Available completed NCT04682808
A Study of FCN-338 in Patients With Chronic CLL/SLL No drug interventions treatment 1 active_not_recruiting NCT01716208
Ofatumumab and Fresh Frozen Plasma in Patients With Chronic Lymphocytic Lymphoma No drug interventions treatment 2 completed NCT02015208
Ruxolitinib in the Treatment of Chronic Lymphocytic Leukemia No drug interventions treatment 1 / 2 completed NCT05326308
Zanubrutinib in Patients With Waldenström's Macroglobulinemia, Chronic Lymphocytic Leukemia, Marginal Zone Lymphoma and Follicular Lymphoma No drug interventions Not Available Not Available recruiting NCT05371808
Economic Analysis of Early vs Delayed Therapy in Newly Diagnosed Asymptomatic High-Risk Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: No drug interventions Not Available Not Available recruiting NCT01460238
Lipoprotein Lipase Expression in Chronic Lymphocytic Leukemia No drug interventions Not Available Not Available completed NCT02991638
Efficacy and Safety of Ibrutinib in Patients With CLL and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus Carriers No drug interventions treatment 3 unknown_status NCT01944943
Phase II Study of Vismodegib in Patients With Refractory or Relapsed B-cell Lymphoma or Chronic Lymphocytic Leukemia No drug interventions treatment 2 terminated NCT04626843
Intermittent Fasting and CLL/SLL No drug interventions treatment 1 completed NCT05899543
Determining Clinical Study Experiences of Chronic Lymphocytic Leukemia Patients No drug interventions Not Available Not Available not_yet_recruiting NCT01133743
Open-Label Study of Lenalidomide in Combination With Oral Dexamethasone in the Treatment of Previously Untreated, Symptomatic Patients With Chronic Lymphocytic Leukemia No drug interventions treatment 2 completed NCT05404282
A Study of AZD6738 and Acalabrutinib in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) treatment 1 active_not_recruiting NCT03852407
Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG Reduced-intensity Conditioning treatment 2 recruiting NCT01518959
The Effect of 25-OH-Vitamin-D3 Substitution in Patients With Malignant and Immune-hematologic Diseases treatment 3 terminated NCT04608318
Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients With Previously Untreated Chronic Lymphocytic Leukaemia (CLL) treatment 3 active_not_recruiting NCT03804372
The Incidence of Hepatitis B in Diffuse Large B-Cell Lymphoma/Chronic Lymphoid Leukemia HBsAg-positive Treated With Rituximab, Chemotherapy and Tenofovir Alafenamide No drug interventions treatment 2 unknown_status NCT04515238
Sequential Regimen of Bendamustine Followed by Obinutuzumab (GA101), Zanubrutinib (BGB-3111) and Venetoclax (ABT-199) in Patients With Relapsed/Refractory CLL No drug interventions treatment 2 active_not_recruiting NCT03787264
Sequential Regimen of Bendamustin-Debulking Followed by Obinutuzumab, Acalabrutinib and Venetoclax in Patients With Relapsed/Refractory CLL No drug interventions treatment 2 completed NCT00788684
Safety Study of ABT-263 in Combination With Rituximab in Lymphoid Cancers No drug interventions treatment 1 active_not_recruiting NCT00406809
A Study of ABT-263 in Subjects With Relapsed or Refractory Lymphoid Malignancies No drug interventions treatment 1 / 2 completed NCT04883749
Efficacy of Acalabrutinib in Very Old or Frail Patients With Treatment-naïve or Relapsed/Refractory CLL No drug interventions treatment 2 active_not_recruiting NCT03766763
Preemptive Therapy for High Risk Chronic Lymphoid Leukemia Stage A No drug interventions treatment 2 recruiting NCT05350826
Evaluation of the Ambulatory Medical Assistance Nurse Program in Chronic Lymphocytic Leukemia No drug interventions other Not Available recruiting NCT04407845
Atrial Fibrillation in Patients Receiving Ibrutinib No drug interventions Not Available Not Available unknown_status NCT02020109
Evaluation of Splenic Irradiation in Chronic Lymphatic Leukemia No drug interventions Not Available Not Available withdrawn NCT01246557
Study Assessing Safety and Efficiency of the Lenalidomide and Dexamethasone Combination in Patients With Chronic Lymphatic Leukemia (CLL) Relapsing or Resistant to Treatment treatment 1 / 2 completed NCT02802943
iVAC-CLL01: Patient-individualized Peptide Vaccination After First Line Therapy of CLL No drug interventions treatment 2 completed NCT01809847
Ofatumumab Induction and Maintenance in Elderly Patients With Poor Risk CLL in the Context of Allogeneic Transplantation No drug interventions treatment 2 completed NCT06508775
Long-Term Follow-up of Patients Treated With Miltenyi Cell and Gene Therapies No drug interventions other Not Available recruiting NCT02273856
Multicentre Registry of Treatments and Outcomes in Patients With Chronic Lymphocytic Leukaemia (CLL) Or Indolent Non Hodgkin's Lymphoma (iNHL) No drug interventions Not Available Not Available terminated NCT05645172
Retention Rate of Acalabrutinib in a Non-interventional Setting No drug interventions Not Available Not Available recruiting NCT02920697
Dose-escalation Study of Oral Administration of S 55746 in Patients With Chronic Lymphocytic Leukaemia and B-Cell Non-Hodgkin Lymphoma No drug interventions treatment 1 completed NCT01279252
CLL Empirical Antibiotic Regimen No drug interventions treatment 2 completed NCT02267590
Tissue Collection for Biomarkers Determining Resistance to Ibrutinib No drug interventions Not Available Not Available unknown_status NCT06357754
Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Secondary Malignancy Not Available Not Available recruiting NCT03582098
Clinical Outcomes and Routine Management of Adults With Chronic Lymphocytic Leukaemia Treated With Idelalisib and Rituximab in the United Kingdom (UK) and Ireland Not Available Not Available completed NCT04728893
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003) treatment 2 recruiting NCT02164071
Validation of a Comprehensive Health Status Assessment Scale in Elderly Patients (≥ 65 Years) With Hematological Malignancies No drug interventions Not Available Not Available completed NCT00802737
Efficacy and Safety of Ofatumumab Retreatment and Maintenance Treatment in Patients With B-cell Chronic Lymphocytic Leukemia (CLL) treatment 4 completed NCT01446900
R-2cda and Prolongation of Therapy With Rituximab Alone in Chronic Lymphocytic Leukaemia and Small Lymphocytic Lymphoma treatment 2 terminated NCT01805375
A Phase I Trial of DI-B4 in Patients With Advanced CD19 Positive Indolent B-cell Malignancies No drug interventions treatment 1 completed NCT01127542
RESPeCT: Revlimid Early Stage Poor Prognosis Chronic Lymphocytic Leukaemia (CLL) Trial treatment 2 terminated NCT00410163
Ofatumumab With Fludarabine and Cyclophosphamide in B-CLL Patients treatment 2 completed NCT01678430
A Trial Looking at Ofatumumab for People With Chronic Lymphocytic Leukaemia Who Cannot Have More Intensive Treatment treatment 3 unknown_status NCT00824265
Ofatumumab Added to Fludarabine-Cyclophosphamide vs Fludarabine-Cyclophosphamide Combination in Relapsed Subjects With Chronic Lymphocytic Leukemia No drug interventions treatment 3 completed NCT02933320
BI-1206 and an Anti-CD20 Antibody in Patients With CD32b Positive B-cell Lymphoma or Leukaemia treatment 1 / 2 completed NCT01110031
Ofatumumab Cardiac Repolarization (QTc) Study in Fludarabine-Refractory Chronic Lymphocytic Leukemia Subjects other 1 completed NCT01039376
Ofatumumab Maintenance Treatment vs No Further Treatment in Relapsed CLL Responding to Induction Therapy treatment 3 terminated NCT00292760
A Single-arm Phase II Study of Alemtuzumab in Combination With High-dose Methylprednisolone in CLL Patients With p53 Deletion treatment 2 completed NCT01453062
Phase IV Observational Study in Chronic Lymphocytic Leukemia Not Available Not Available completed NCT00748189
Ofatumumab + Chlorambucil vs Chlorambucil Monotherapy in Previously Untreated Patients With Chronic Lymphocytic Leukemia No drug interventions treatment 3 terminated NCT01563055
A Phase I/II, Open-label Study of Ofatumumab Added to Chlorambucil in Previously Untreated Japanese Patients With Chronic Lymphocytic Leukemia No drug interventions treatment 2 completed NCT06564038
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies No drug interventions treatment 1 / 2 not_yet_recruiting NCT01832597
Efficacy and Safety Study of Bendamustine With or Without Rituximab in Chronic Lymphoproliferative Disorders No drug interventions Not Available Not Available completed NCT04763083
First in Human Study of NVG-111 in Relapsed/Refractory ROR1+ Malignancies No drug interventions treatment 1 recruiting NCT00349349
HuMax-CD20 in B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients Failing Fludarabine and Alemtuzumab No drug interventions treatment 2 completed NCT01597219
Trial of Haploidentical Stem Cell Transplantation for Haematological Cancers No drug interventions treatment 2 completed NCT00751296
Study of Lenalidomide in Previously Untreated, Symptomatic Chronic Lymphocytic Leukemia (CLL) No drug interventions treatment 2 terminated NCT01077622
A Phase I/II, a Single Arm, Open-label Study of Ofatumumab (GSK1841157) in Patients With Previously Treated Chronic Lymphocytic Leukemia No drug interventions treatment 2 completed NCT00457782
A Phase I Safety, PK and PD Study of KW-2478 in Patients With Multiple Myeloma, Chronic Lymphocytic Leukaemia or B-cell Non-Hodgkin's Lymphoma No drug interventions treatment 1 completed NCT00504491
R-CHOP and Alemtuzumab in Patients With Chronic Lymphocytic Leukemia No drug interventions treatment 2 withdrawn NCT01659255
Study to Evaluate the Safety and Tolerability of Tirabrutinib (ONO/GS-4059) Given as Monotherapy in Participants With Relapsed/Refractory NHL and CLL No drug interventions treatment 1 completed